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PREFACE 
 
   Surgery, chemotherapy and radiation therapy are three well-established treatment 
modalities for animals with cancer disease in veterinary medicine. Radiation therapy is a 
form of disease treatment by using ionizing radiation. The discovery of X-rays by Wilhelm 
Conrad Röntgen in 1895 followed by Richard Eberlein, a German physician and 
veterinarian, began to use radiation for tumor therapy in animals in 1907. Alois Pommer, an 
Austrian veterinarian, published widely on irradiation of diseases and established a radiation 
therapy protocol in 1958 [28, 53]. Radiation therapy is becoming increasingly available and 
in demand in companion animals with cancers. Recently, there has been an increase in 
information on its effectiveness in the treatment of a number of different tumor types [59, 
60]. 
   Radiation therapy is a form of medical treatment using high-energy waves or particles to 
destroy or damage cancer cells. The common radiation sources include beams of x-rays, 
gamma rays or electrons delivered by either orthovoltage or megavoltage radiation therapy 
equipment in veterinary medicine [60]. Ionizing radiation may kill cells causing damage of 
DNA either directly or indirectly within tissue. Unlike with direct action, most the time 
ionizing radiation interacts with water molecules near the DNA hence creating free radicals, 
which damage the DNA [28, 62]. Cells may undergo apoptosis when the DNA damage is 
irreparable. Cells that are in M and in G2 phase during the cell cycle are the most sensitive 
to radiation damage. The cells become more resistant as they proceed through G1. They 
even become the most resistant as they reach the S phase [62].   
   Nasal tumors develop in several tissue types that are found in the nasal and sinus 
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cavities within the head. However, they are uncommon and only account for less 2% of all 
canine tumors [97]. Most dogs presenting nasal tumors are middle to old age. 
Dolichocephalic breeds may be at increased risk for developing nasal tumor. Clinical signs 
in dogs with nasal tumor include epistaxis, sneezing, mucopurulent discharge, facial 
deformity, exophthalmos, and occasionally neurologic abnormalities. Nasal tumors are 
commonly very aggressive to the surrounding tissues. A cross-sectional imaging allows to 
accurate determination of the localization and extension of tumor. Metastatic rate is 
generally considered low at the time of diagnosis [23, 103]. Biopsy and histology of the 
tumor are needed for definitive diagnosis, even though historical information and diagnostic 
imaging are able to be highly suggestive. In dogs, nasal tumors are nearly all malignant. 
Approximately two thirds are epithelial in origin (carcinoma). The remaining tumors are 
mesenchymal in origin (sarcoma) [1, 23, 50, 74]. Other types of tumor, such as 
transmissible venereal tumor, melanoma, and lymphoma, have been also reported 
previously [32, 42, 71].  
   A variety of treatments for nasal tumors have been reported, including surgery, 
chemotherapy, radiation therapy, cryosurgery, or a combination of these modalities. 
Recently, the preferred treatment of nasal tumor is radiation therapy, which is the most 
effective therapy for this disease due to the nature behavior of nasal tumors [23, 31, 47]. 
Dogs with nasal tumors that remain untreated have a median survival time (MST) of 1.5 to 
3 months [74, 108]. On the other hand, MSTs after radiation therapy of nasal tumors vary 
significantly depending on clinical stage, histological type, and metastasis, but generally 
range from 7 to 23 months in previous studies [1, 50, 68, 97]. 
   Immunohistochemistry studies have been broadly used to evaluate molecular markers as 
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well to search valuable biomarkers associated with prognosis in human medicine. Recently, 
a high number of biomolecular tumor markers such as EGFR, VEGF, survivin, COX-2, 
LMP1, Ki-67, cyclin-D1, and p63 [16, 18, 48, 55, 69, 93, 100, 106, 107, 112] have been 
investigated for prognosis and/or therapeutic targets in human nasopharyngeal carcinomas 
(NPC). These studies have attempted to elucidate the molecular mechanisms associated 
with NPC carcinogenesis. Few researches were performed in canine nasal tumors. In one 
study that Gamblin et al. published, nuclear p53 protein accumulation was detected in 11 of 
19 nasal adenocarcinomas. This suggested that overexpression of a mutated p53 tumor 
suppressor gene protein might be a reliable form of prognostic predictor [27]. COX-2 
expression has been detected in most canine nasal epithelial tumors (71-90%) [6, 13, 45, 36]. 
Expression of EGFR and VEGF were detected in over 50% and 90% of 24 nasal carcinoma 
samples, respectively [83]. In addition, activity of matrix metalloproteinase-2 (MMP-2) was 
detected in one-thirds of nasal adenocarcinomas (4 of 12 samples) [66]. However, few 
number of studies have been investigated the association between the biomarker and 
outcome for canine nasal tumors. 
   Enhanced radiosensitivity of the tumor cells might to be an optimal strategy for 
improving tumor response to radiation therapy [84]. The mechanisms of cellular malignant 
transformation include the regulation of signal transduction, cell differentiation, apoptosis, 
DNA repair, cell cycle progression, and angiogenesis. Applications of molecular 
radiobiology in recent years have altered the understanding of tumor radioresistance and the 
cellular response to ionizing radiation [57]. Some biological agents designed to target these 
molecular progresses have shown both radiosensitizing and antiproliferative activities in 
preclinical models of human cancers [14, 30, 39, 57, 101, 105, 110]. Several studies have 
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used various ways to enhance such radiosensitivity. These include p53 transfection, COX-2 
antagonist (celecoxib), multi-targeted receptor tyrosine kinase inhibitor (sunitinib), survivin 
suppressant (YM155), EGFR inhibitors (gefitinib, cetuximab), and some chemotherapeutic 
agents [39, 54, 84, 110].  
   This thesis is composed of three chapters. In Chapter I, we evaluated the outcomes for 
dogs with nasal carcinoma with clinical variables and to compare survival times for dogs 
treated with radiation therapy in a decade in RGU. Chapter II is to emphasize on evaluation 
of tumor markers (Ki-67, survivin, EGFR, VEGF, and COX-2) expression and apoptotic 
index in canine nasal carcinoma through an immunohistochemical staining and TUNEL 
assay. We also seek correlations among these tumor markers, clinical variables, and the 
outcomes after radiation therapy. In Chapter III, a cell line of canine nasal squamous cell 
carcinoma and a radioresistant subclone cell line are established. This chapter then 
compares differences between the radiosensitive and radioresistant cell line. Additionally, 
base on the protein expression in canine nasal carcinomas in the results of Chapter II, we 
also evaluate the radiosensitizing effect of molecular targeted therapeutic agents in the nasal 
SCC cell line.
 7 
 
 
 
 
 
CHAPTER I. 
 
 
Retrospective Study of Prognostic Indicators in Dogs with Nasal 
Carcinoma Treated with Radiation Therapy in RGU: 2004-2013
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1. INTRODUCTION 
 
   Canine nasal tumors are uncommon, accounting for 1% to 2% of all neoplasms in dogs 
[97]. However, they are nearly all malignant. Approximately 60% to 75% of canine nasal 
tumors are carcinomas, epithelial-origin. The subtypes of nasal carcinomas include 
adenocarcinomas, squamous cell carcinomas, transitional cell carcinomas, and 
undifferentiated carcinomas [1, 47, 50, 74]. Adenocarcinoma is the most common tumor 
type of all nasal tumors in dogs [1, 31, 47].  
   Most canine nasal tumors are very invasive to the surrounding tissue but are less likely 
to metastasize. The rate of metastasis is reported to be from 10% to 14% of all nasal tumor 
cases at the time of diagnosis in previous reports [15, 31, 50, 58]. There is a study reporting 
a higher metastatic rate (24%) in dogs with nasal carcinomas [74].  
   Several studies have reported the negative prognostic factors in canine nasal tumor, 
including age greater than 10 years [50], presence of epistaxis at time of diagnosis [50], 
regional lymph nodes or lung metastasis [31, 50], cribriform plate destruction on computed 
tomography (CT) images [1], and tumor histological subtype [1, 97]. Previous reports 
trended to show shorter survival time for dogs with carcinoma than those with sarcoma. 
Some studies reported better prognosis for dogs with adenocarcinoma comparing to those 
with squamous cell carcinoma or undifferentiated carcinoma [1, 2, 97]. The median survival 
time (MST) of dogs with nasal carcinomas had a range of 7-13 months [1, 50, 68, 97]. 
   Nasopharyngeal tumor staging in humans has commonly been utilized with CT images. 
Some clinical staging methods based on CT images also have been used for canine nasal 
tumor staging [1, 2, 47, 50, 97]. A WHO three-tiered staging method was performed with 
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radiographic or CT findings but prognostic significance was not found [2, 47]. Likewise, the 
WHO staging system was modified to two-tiered staging method and applied to CT findings, 
which be observed no prognostic significance [47]. A CT-based four-tiered staging method, 
modified from human nasopharyngeal carcinoma staging method, published by Adams et al. 
in 2009 and has recently been used in several investigations [1, 58, 90].  
   A variety of treatments for nasal tumors have been reported, including surgery, 
chemotherapy, radiation therapy, cryosurgery, or a combination of these modalities. 
Although chemotherapy has been attempted as primary therapy [52], as an adjuvant therapy 
[51], or as a radiosensitizer [54], chemotherapy has not improved survival of dogs with 
nasal tumors. Surgery has also been attempted for local therapy as a sole treatment [31, 90] 
or with an adjuvant radiation [2, 68]. Due to the complex surrounding anatomical structure, 
nasal tumors are difficult to treat with surgery alone to prolong survival time. Radiation 
therapy is considered an effective as well as relatively noninvasive therapy for local control 
of canine nasal tumors.  
   The goals of this chapter were to describe the outcomes for dogs with nasal carcinoma 
according to clinical variables. We also compared the survivals for dogs treated with 
radiation therapy in a decade in our university veterinary teaching hospital. 
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2. MATERIALS AND METHODS 
 
(1) Patients data 
   The medical records of 84 dogs diagnosed with nasal carcinomas in the Rakuno Gakuen 
University Veterinary Teaching Hospital (RGU-VTH) between April 2004 and January 2014 
were reviewed. All dogs had biopsy taken before treatment and had been diagnosed with 
carcinomas by histopathology. Data collected from the medical records, including age, sex, 
body weight, breed and clinical signs. Pretreatment evaluation included a complete blood 
count, serum chemistry, three-view thoracic radiographs, CT scans, and a fine-needle biopsy 
of regional lymph nodes if enlarged. Follow-up information was obtained from the medical 
records or by contacting the referring veterinarians. Endpoints were assigned as follow: 
alive if the dog was known to be alive at the time of data collection, lost to follow-up if 
survival status was unknown at the time of data collection, or dead if the dog had died 
before data collection.  
 
(2) CT images evaluation 
   All the dogs enrolled in this chapter had taken CT scans before biopsy and treatment. 
All CT images of the archived dogs at the time of initial presentation were reviewed. CT 
images evaluation was evaluated for the absence or presence of lesions, location of the 
lesions (unilateral or bilateral), osteolysis (nasal septum, frontal sinus, hard palate, 
cribriform plate), and invasiveness (frontal sinus, orbit cavity, subcutis, oral cavity, 
nasopharynx or cranial cavity). Clinical staging was based on CT imaging using Adams’ 
modified staging system [1] (shown in Table 1-1). 
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(3) Radiation therapy and response assessment 
   Radiation therapy was performed by use of an orthovoltage X-ray machine 
(TITAN-450S, GE) with a half-value layer of 4.8 mm of Cu at 450 KV and 10 mA. The 
exposure rate was 1.68 Gy/min with a filter of 1.0 mm of Al, 0.3 mm of Cu and 0.5 mm of 
Sn. The distance from the X-ray source to the skin was 60 cm. Treatment protocols 
including dose per fraction, number of fractions, treatment schedule, total radiation dose, 
and field sizes were recorded.  
   The response to treatment was assessed based on the RECIST system with CT images 
around one month after completion of radiation. Contrast medium was used to distinguish 
contrast-enhanced tissues from nasal discharge. Complete response (CR) was determined if 
the tumor disappeared from CT images. Partial response (PR) was defined as a decrease of 
30% or greater in the sum of the longest diameters. Stable disease (SD) was defined as 
between a decrease of 30% and an increase of 20% in the sum of the longest diameter. 
Progressive disease (PD) was defined as an increase of 20% or greater in the sum of the 
longest diameters [98].  
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(4) Statistical analysis 
   The overall survival time of a patient was calculated from the starting date of radiation 
therapy to the time of death or the last follow-up. The progression-free survival (PFS) was 
defined from the starting date of radiation therapy to the day of disease progression or the 
last follow-up. The correlation between the survival and prognostic factors was estimated 
using Kaplan-Meier survival curves, and statistical differences between survival curves 
were calculated using a log-rank method. P values of < 0.05 were considered statistical 
significant. The commercial software StatMate III (ATMS Co., Ltd.) was used to perform 
the statistical analysis.  
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3. RESULTS 
 
(1) Patient and tumor characteristics 
   The information of 84 dogs is summarized in Table 1-2. The mean and median ages for 
sampled dogs were 10.9 years and 11 years (range from 6 to 16 years of age), respectively. 
There were 15 intact females, 26 spayed females, 19 intact males and 24 neutered males. 
There were 72 pure-breed dogs and 11 mixed breed dogs. Golden retriever (n = 13), 
Pembroke Welsh corgi (n = 12) and miniature dachshund (n = 7) were the most three 
pure-breeds. 
   Histopathological examination revealed 36 dogs (42.8%) diagnosed with 
adenocarcinomas (ADC), 23 dogs (27.4%) diagnosed with undifferentiated carcinomas 
(CA), 13 (15.5%) dogs diagnosed with squamous cell carcinomas (SCC) and 12 dogs 
(14.3%) diagnosed with transitional cell carcinomas (TCC). Ten dogs had regional lymph 
nodes metastasis, one dog had lung metastasis, and one dog had regional lymph nodes and 
lung metastasis at the time of initial presentation. The rate of metastasis was 14.3% in 84 
dogs. 
   The clinical signs revealed epistaxis in 56 dogs (66.7%), nasal discharge in 43 dogs 
(51.2%), sneezing in 31 dogs (36.9%), facial deformity in 28 dogs (33.3%), exophthalmos 
in 15 dogs (17.9%), and neurological abnormalities in 9 dogs (7.1%). The clinical signs and 
tumor subtypes were summarized in Table 1-3. Compared with the other histological 
subtypes, facial deformity (19.4%) and exophthalmos (5.6%) were present significantly less 
in dogs with ADC (P = 0.018 and 0.026, respectively). Nasal discharge (15.4%) was seen 
significantly less in dogs with SCC (P = 0.035). The presences of epistaxis, sneezing and 
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neurological abnormalities were not significantly associated with tumor subtype. 
   On CT evaluation, 59 dogs had unilateral disease (33 dogs were left; 26 dogs were right 
lateral) and 25 had bilateral disease. The CT findings showed frontal sinus involvement in 
28 dogs (33.3%), orbital involvement in 32 dogs (38.1%), subcutaneous involvement in 38 
dogs (45.2%), oral involvement in 14 dogs (16.7%), nasopharyngeal involvement 13 dogs 
(15.5%), and cribriform plate destruction in 39 dogs (46.4%). The CT findings and tumor 
subtype were summarized in Table 1-4. Involvement of oral cavity (25%) and nasopharynx 
(25%) were trended to see more often in dogs with ADC, but they were not significant (P = 
0.076 and 0.074, respectively). Dogs diagnosed with CA occurred most commonly 
destruction of cribriform plate (65.2%) (P = 0.033). Nasopharyngeal involvement (0%) was 
detected significantly less in dogs with SCC (P = 0.046). The presences of frontal sinus, 
orbital, and subcutaneous involvement were not significantly associated with tumor subtype. 
According to the Adams’ proposed stage classification, thirteen dogs were staged as T1 
disease (15.5%), 8 dogs as T2 disease (9.5%), 24 dogs as T3 disease (28.6%), and 39 dogs 
as T4 disease (46.4%).  
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(2) Treatment methods 
   Fifty-nine of the 84 dogs received radiation therapy. There were 28 dogs with ADC, 16 
dogs with CA, 10 dogs with SCC, and 5 dogs with TCC. The median of the irradiation 
dose/fraction was 4 Gy (range of 3-6 Gy). One or two directions were carried out for each 
fraction. Radiation was delivered via a dorsal portal directed to the tip line of the nose to the 
top of the head with/without an additional ventral portal directed from oral side. The 
irradiated fields were assessed by CT images. Treated tumor volume included a 1-2 cm 
margin of normal tissue. Two to three fractions weekly (Monday-Friday schedule or 
Monday-Wednesday-Friday schedule) were performed. Dogs received a total skin surface 
dose of 30 to 48 Gy (mean of 41.2 Gy, median of 40 Gy). Treatment duration ranged from 
21 to 46 days (mean of 32 days, median of 30 days). One dog also received chemotherapy 
with carboplatin and cyclophosphamide, and two other dogs received zoledronic acid 
(Zometa®) during treatment. One dogs received toceranib phosphate (Palladia®) after 
radiation therapy. Ten dogs were treated with laser therapy by rhinoscopy, and one dog was 
treated with photodynamic therapy after the end of radiation therapy. Two dogs with 
regional lymph node metastasis was also received irradiation with the mandibular lymph 
nodes. 
   Fifty-five of 59 dogs had CT scan taken after radiation therapy and were available to 
determine the response by radiation therapy. Thirty-five dogs were determined to have a 
partial response (PR) (19 ADC, 11 CA, 2 SCC and 3 TCC), and twenty dogs had a stable 
disease (SD) in response to radiation therapy (7 ADC, 4 CA, 8 SCC and 1 TCC). The 
overall response rate was 63.6% (35/55) in dogs with nasal carcinomas; the response rates 
of dogs with ADC, CA, SCC and TCC were 73.1% (19/26), 73.3% (11/15), 20% (2/10) and 
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75% (3/4), respectively. 
   Twenty-two of 84 dogs did not receive treatment (8 ADC, 7 CA and 7 TCC). Besides, 
two dogs diagnosed with SCC were treated with surgery alone. One dogs with SCC 
received photodynamic therapy in another university.  
 
(3) Follow-up and survival analysis 
   Of 59 dogs that received radiation therapy, 48 dogs were dead (29 dogs due to tumor 
progression, two dogs due to euthanasia, seven dogs due to other diseases and ten dogs 
unknown), seven dogs were lost to follow-up and four dogs were still alive at the time of 
data analysis. Fourteen of 22 dogs that were not treated died due to tumor progression, two 
dogs were lost follow-up at 90 and 258 days, and six dogs were lost follow-up after the time 
of initial presentation. One dogs treated with photodynamic therapy survived 761 days. Of 
two dogs received surgery alone, one dog survived 1765 days and one dog was lost to 
follow-up at 139 days. 
   The median overall survival time (MST) for 59 dogs that treated with radiation therapy 
was 241 days (ranged from 40 to 1979 days). The 16 dogs that received no treatment had a 
MST of 95 days (ranged from 9 to 206 days) (Figure 1-1). The median of progression-free 
survival (PFS) for 59 dogs that treated with radiation therapy was 176 days (ranged from 30 
to 1979 days) (Figure 1-2).  
   The survival curves of dogs diagnosed with each histological subtype show in Figure 
1-3. The dogs diagnosed with nasal ADC had MST and median PFS of 242 days and 221 
days. The overall MST and median PFS for dogs with nasal CAs was 254 days and 90 days, 
respectively. The nasal SCC dogs had MST and median PFS of 178 days and 148 days. And, 
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the dogs diagnosed with nasal TCC had MST and median PFS of 407 days and 186 days. 
The MSTs for nasal ADC, CA and TCC dogs that did not receive treatment were 103 days, 
104 days and 79 days, respectively. No significant differences were observed among 
histological tumor types. 
   Median PFSs and MSTs for tumor stages, for all carcinomas and each subtype 
carcinomas were summarized in Table 1-5. Dogs with high-stage were showed poor 
prognosis in all type of nasal carcinomas. The MST for dogs with T1, T2, T3 and T4 was 
461 days, 407 days, 262 days and 170 days, respectively (Figure 1-4). Six dogs with T4 
disease diagnosed metastasis at initial presentation were excluded from T4 group in survival 
analysis. 
   The median PFSs and MSTs according to different clinical variables were summarized 
in Table 1-6, 1-7 and 1-8. In clinical signs (Table 1-6), nasal discharge, facial deformity and 
exophthalmos were significantly associated with PFS (P < 0.001, = 0.034 and < 0.001, 
respectively). Nasal discharge, exophthalmos and neurological abnormalities were closely 
correlated with overall survival time (P = 0.005, 0.014 and 0.007, respectively). Presence of 
nasal discharge was however a positive prognostic factor in dogs with nasal carcinoma. 
Neither epistaxis nor sneezing was significantly associated with survival. 
   In CT findings (Table 1-7), the dogs that detected orbital, subcutaneous involvement and 
cribriform plate destruction had significantly shorter PFS than those that did not detect (P = 
0.012, 0.005 and < 0.001, respectively). Furthermore, the dogs with orbital involvement and 
cribriform plate destruction were also closely correlated with shorter overall survival times 
(P = 0.007 and < 0.001, respectively). However, frontal sinus, oral and nasopharyngeal 
involvements did not significantly affect the survivals.  
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   Body weight, sex and irradiation dose were not found significant association with 
survivals. Dogs with metastasis had a significantly shorter PFS than those without 
metastasis (P = 0.002). Dogs with a PR were significantly correlated with a longer PFS than 
those with an SD (P = 0.016). Additionally, dogs with an age less than 11 years had longer 
survival than dogs with an age greater than 11 years (P = 0.033). Metastasis and RT 
response also had significant correlations with survival times (P = 0.006 and 0.007, 
respectively) (Table 1-8).
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Figure 1-1. Kaplan-Meier survival curves for the overall survival time of dogs with nasal 
carcinoma treated with radiation therapy (n = 59) and without any treatment (n = 16). The 
MST of the dogs treated with RT and without treatment was 241 days (range: 40 to 1979 
days) and 95 days (range: 9 to 206 days), respectively.  
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Figure 1-2. Kaplan-Meier survival curve for the progression-free survival (PFS) of dogs (n 
= 59) with nasal carcinoma treated with radiation therapy. The median PFS was 176 days 
(range: 30 to 1979 days). 
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Figure 1-3. Kaplan-Meier survival curves for the overall survival time of dogs with nasal 
carcinoma treated with RT according to tumor histological subtype. The MST of the dogs 
diagnosed with adenocarcinoma (ADC; n = 28), undifferentiated carcinoma (CA; n = 28), 
squamous cell carcinoma (SCC; n = 10) and transitional cell carcinoma (TCC; n = 5) was 
242 days (range: 79 to 1979 days), 254 days (range: 40 to 1558 days), 178 days (range: 92 
to 497 days) and 407days (range: 54 to 648 days), respectively. 
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Figure 1-4. Kaplan-Meier survival curves for the overall survival time of dogs with nasal 
carcinoma treated with RT according to tumor clinical stage. The MST of the dogs staged as 
T1 (n = 9), T2 (n = 7), T3 (n = 18) and T4 (n = 19) was 461 days (range: 106 to 1979 days), 
407 days (range: 236 to 678 days), 262 days (range: 92 to 1641 days) and 170 days (range: 
40 to 639 days), respectively. 
 
 
 
 
 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26 
 
 
 
 
 
 
 
 
 
 
 
 
 27 
 
 
 
 
 
 
 
 
 
 
 
 
 28 
 
 
 
 
 
 
 
  
 29 
4. DISCUSSION 
 
   Canine nasal tumors of epithelial origin are more common than those of mesenchymal 
origin. And, dogs with nasal carcinoma trended to show worse prognosis than those with 
nasal sarcoma [1, 47, 97]. Few studies have evaluated outcome of dogs treated for various 
histological subtypes of nasal carcinomas [31, 74]. It would be helpful to evaluate the tumor 
characteristics and to seek the prognostic utilities in dogs with nasal carcinoma. 
   Clinical signs in dogs with nasal tumor include epistaxis, sneezing, mucopurulent 
discharge, facial deformity, exophthalmos, and occasionally neurologic abnormalities [103]. 
The clinical signs among tumor histologic subtypes were compared in this chapter. Facial 
deformity and exophthalmos were not likely showed in dogs with ADC. Nasal discharge 
was not likely to seen in dogs with SCC. These results indicated the different tumor clinical 
features among canine nasal carcinoma subtypes. 
   Cross-sectional imaging has been commonly preformed to investigate the sinonasal 
diseases. CT image allows to accurate determination of the extent and behavior of tumor in 
sinonasal cavities [1, 2, 47, 50, 97]. Nasal tumors are commonly very aggressive to the 
surrounding tissues including orbit, oral cavity, subcutis, nasopharynx or brain. Thirty-nine 
of 84 (46.4%) dogs with nasal carcinomas showed osteolysis of the cribriform plate and 
extent to the brain. Cribriform plate destruction (65.2%) on CT images in dogs with CA was 
detected frequently. Oral and nasopharyngeal involvement were most likely to be ADC. 
Nasopharyngeal involvement was however detected infrequently in dogs with SCC in this 
chapter. 
   The MST for all patients with nasal carcinoma treated with radiation therapy in this 
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chapter was approximately 8 months (241 days). The dogs with nasal carcinoma that did not 
receive treatment had a MST of 3.1 months (95 days) in our study. It is similar to the 
previous report [74]. Regarding histological subtypes, some studies reported better 
prognosis for dogs with ADC compared to those with SCC or CA [1, 2, 97]. In our study, 
the rate of response to treatment in dogs with SCC was lower than in dogs with ADC, CA or 
TCC (20% versus 73.1%, 73.3% and 75%). The dogs with SCC showed the worst response 
rate of all nasal carcinomas and had the shortest MST of 178 days comparing with ADC’s 
MST of 242 days, CA’s MST of 254 or TCC’s MST of 407 days. Although no significant 
difference in survival time was observed among tumor subtypes, nasal SCC was suggested 
to be the most radioresistant tumor type in canine nasal carcinomas due to the worst 
response rate to radiation therapy. 
   Epistaxis has been the most common clinical sign in nasal tumors at the time of 
diagnosis [47, 68, 74]. It was similar in our study. Two-thirds of dogs were present nasal 
hemorrhage. One published study has reported that the dogs with epistaxis had worse 
prognosis than those without epistaxis [74]. However, no significant differences were found 
in this chapter. Surprisingly, longer median PFS and MST for dogs with nasal discharge 
than those without nasal discharge were found in our study. When nasal cavity is filled with 
tumor tissues, nasal discharge may not be present due to an obstructed nasal cavity. It is 
thinkable to show a worse prognosis for dogs without nasal discharge. The presence of 
facial deformity or exophthalmos was a negative prognostic factor for PFS. Facial 
deformity has been reported as a negative prognostic indicator [68]. Dogs with facial 
deformity and exophthalmos would be thought to have more invasive tumors resulting more 
difficult local control. Additionally, a nasal tumor that destroyed cribriform plate and then 
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invaded to the brain would occur neurological signs. Neurological abnormalities were 
present in dogs with T4 disease. Therefore, the presence of neurological abnormality was 
also showed to be a prognostic significance in nasal carcinomas. 
   The prognostic significances have been evaluated according to CT finding, with the 
finding that response to therapy is significantly related to specific location of tumor 
invasion [1, 47, 50, 97]. Dogs with subcutaneous involvement (148 days) had significantly 
shorter PFS than those that did not involve subcutis (246 days). Involvement of orbit and 
destruction of cribriform plate were highly associated with both short PFS and overall 
survival time. It is indicated that more aggressive tumors were more difficult to local control 
resulting poor prognosis. Like nasopharyngeal tumor staging in humans, CT images have 
commonly been attempted to utilize for canine nasal tumors [1, 2, 47, 50, 97]. Adams’ 
modified staging system that published in 2009 was performed in our study (Table 1-1). It 
has recently been used in several reports [1, 58, 90]. In our study, sixty-three of 84 (75%) 
dogs were classified as T stage of T3 to T4 (late stage) with 39 (46.4%) in stage T4. 
Treating with radiation therapy, stage T3- and T4-dogs had worse prognosis than early 
stages (T1 and T2). Among histological subtypes, the T4 stage of dogs diagnosed with CA 
had the shortest median PFS (81 days) and MST (111 days) (TCCs were excluded form 
statistical analysis due to small numbers). The T4 stage of ADC dogs had better survival 
comparing with of CA and SCC dogs (Table 1-5). However, additional study with a larger 
cohort of canine nasal carcinomas may still be necessary. 
   There were 12 cases of metastasis to regional lymph nodes and/or lung at the time of 
diagnosis. This finding was similar to a previously reported a metastatic rate of 10-14% for 
nasal tumors [15, 47, 50, 90]. The dogs with metastatic lesions had significantly shorter PFS 
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(77 days) and MST (98 days) than dogs without metastasis. Metastatic status has been also 
previously described for dogs with nasal tumor [47, 50]. Due to using of an orthovoltage 
machine, lower energy of radiation, in our study, radiation could not deliver enough to the 
deeper tissues. Large-breed dogs may not be superior to small-breed dogs. However, 
significant differences of survival were not observed between the dogs with weight of > 15 
kg and those with weight of < 15 kg. On the other hand, although the treatment schemes 
were heterogeneous in our study and the total dose of irradiation also affected survival in an 
earlier study [90], the dogs that received radiation dose of > 40 Gy were not found to have 
significant influence for survivals in this chapter. Radiosensitivity of tumors is associated 
with the outcome of treating with radiation. Dogs with a PR were found longer PFS and 
overall survival time than dogs with an SD. This result suggested that to grasp the 
mechanisms of radiosensitivity is necessary in canine nasal carcinomas. 
   Despite the limitations of nature of a retrospective study, some prognostic significances 
of canine nasal carcinoma were interpreted in this chapter. In the next chapter, we would 
evaluate the expression of tumor markers in canine nasal carcinoma and seek correlations 
between tumor markers and clinical variables. 
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5. SUMMARY 
 
   One of the goals of this chapter was to identify prognostic indicators for survival in dogs 
with nasal carcinoma treated with radiation therapy. Dogs diagnosed with SCC had the 
lowest response rate (20%) in all carcinoma types. The dogs with SCC also showed the 
shortest survival times in this chapter. Additional negative prognostic factors for PFSs or 
overall survival times were observed in this chapter, including presence of facial deformity, 
exophthalmos and neurologic abnormalities and absence of nasal discharge at initial 
presentation, orbital and subcutaneous involvement, cribriform plate destruction on CT 
images at time of diagnosis, age greater than 11 years, regional lymph nodes or lung 
metastasis, and the response to treatment. 
   It would be useful to grasp the mechanisms of radiosensitivity in canine nasal 
carcinomas. The mechanisms of cellular malignant transformation include the regulation of 
cell cycle, cell differentiation, apoptosis, and angiogenesis. Applications of molecular 
radiobiology in recent years have altered the understanding of tumor radioresistance and the 
cellular response to ionizing radiation. We would put emphasis on expression of tumor 
markers via imuunohistochemistry staining in canine nasal carcinoma. We would also seek 
the correlations between tumor markers and prognostic significances in the next chapter. 
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1. INTRODUCTION 
 
   In recent years, despite a large number of studies for prognostic factors of radiation 
therapy in human medicine, very little research has been performed in veterinary study. 
Chapter II was to put emphasis on evaluation of tumor markers expression in dogs with 
nasal carcinoma. This chapter is also to seek a correlation between tumor markers and 
clinical variables. It is important to search valuable biomarkers involving canine nasal 
carcinomas for therapeutic targets that may lead to more effective treatment of dogs with 
nasal carcinoma.  
   Ki-67 is a nuclear protein that is widely used to detect proliferative cells. It is present in 
proliferating cells during the G1, S, G2, and M phases of the cell cycle however it is absent 
during the resting phase (G0). A high positive rate of Ki-67 has been generally considered to 
be an unfavorable prognostic factor in several human and veterinary studies [7, 67, 81, 88].  
   Survivin is a small protein that belongs to the inhibitors of apoptosis protein (IAP) 
family. It is not expressed in normal differentiated tissue but highly expressed in fetal 
tissues and several cancers [41]. The expression of survivin is associated with poor 
prognosis in several human cancers [46, 55]. In humans, 60-78.6% of nasopharyngeal 
carcinomas (NPC) are positive for survivin expression [55, 107, 111]. In veterinary 
medicine, the expression of survivin also has been detected in several tumors in dogs such 
as mast cell tumors [81], lymphomas [75], urinary bladder transitional cell carcinomas [73], 
squamous cell carcinomas [8], osteosarcomas [86], skin tumors [9, 11], and mammary 
tumors [10]. Survivin expression is correlated with malignancy in these tumors. 
   Epithelial growth factor receptor (EGFR) is a transmembrane protein of ErbB family of 
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receptor tyrosine kinase (RTK). Binding of epithelial growth factor (EGF) or EGF-like 
growth factors activates the receptor and then triggers the cascades of signal transduction. 
EGFR plays a key role in regulation of cell cycle, angiogenesis, differentiation and survival 
[18, 25, 83] Overexpression of EGFR has been correlated with poor prognosis in human 
cervical [25] and nasopharyngeal cancers [16, 18, 93]. The inhibition of EGFR improves the 
treatment response of radiation therapy or chemotherapy in human head and neck 
carcinomas [18, 34]. EGFR also expresses in several canine tumors, including nasal 
carcinomas [83], mammary gland tumors [26], and lung tumors [79]. Over 70% of human 
nasopharyngeal carcinomas and 54.2% of canine nasal carcinomas were detected EGFR 
expression [18, 69, 83]. 
   Vascular endothelial growth factor (VEGF) belongs to the platelet-derived growth factor 
(PDGF) family. It is a dimeric glycoprotein and is secreted by macrophage, vascular smooth 
muscle cells, and tumor cells to stimulate endothelial migration and proliferation [29, 33]. 
VEGF regulates angiogenesis by binding to a number of vascular endothelial growth factor 
receptors (VEGFRs) [4]. The growth of a solid tumor requires an adequate blood supply, 
which is enabled by vascular formation (angiogenesis) [29]. Tumor angiogenesis is related 
to tumor development, progression, and metastasis [33]. VEGF production can be induced 
in cells that lack oxygen. In human NPC, overexpression of VEGF is correlated with the 
presence of metastasis and recurrence [55]. There is a link between VEGF expression and 
poor outcome post radiotherapy in NPC [35]. In canine nasal carcinomas, positive rate for 
VEGF staining was 91.7% [83]. 
    Cyclooxygenase (COX) is a rate-limiting enzyme in prostaglandin endoperoxide 
synthesis from arachidonic acid. COX-2, an inducible isoform of cyclooxygenase, is 
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generally undetectable in normal tissues but is induced by some pro-inflammatory cytokines, 
growth factors and tumor promoters [6, 13, 45]. Expression of COX-2 is related to 
apoptosis inhibition, tumor metastasis and angiogenesis [69, 91]. Increased COX-2 
expression was associated with poor prognosis in NPC [17, 70]. A high positive rate of 
71-90% of nasal carcinomas in dogs expressed COX-2 [6, 13, 36, 45]. Expression of 
COX-2 has been reported to use to predict the prognosis of canine nasal carcinomas that 
were treated with hypofractionated radiotherapy. However there was no significant 
correlation between survival and COX-2 score [6].  
   Apoptosis is the process of eliminating old and damaged cells in tissues. It is mediated 
through a number of proteins involved in the activation of caspases cascades [102]. The 
biochemical level of changes lead to cell morphology, which include membrane blebbing, 
cell shrinkage, chromatin condensation, and DNA fragmentation. Radiation will induce 
apoptosis in neoplastic cells [78, 102]. A correlation between spontaneous and 
radiation-induced apoptosis rates has been observed in several studies [78, 82]. These 
studies revealed that patients with an increased spontaneous apoptotic rate had a good 
prognosis in human bladder [77], cervical [82] and rectal [3, 76, 94] cancers treated with 
chemoradiation/radiation therapy. 
   The primary goal of this chapter was to evaluate the expression of Ki-67, survivin, 
EGFR, VEGF, and COX-2 in canine nasal carcinomas through immunohistochemical (IHC) 
staining in tumor tissues. Secondary goal was to seek a correlation between these markers 
and prognosis after radiation therapy. 
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2. MATERIALS AND METHODS 
 
(1) Biopsy samples and patient data 
   Biopsy samples obtained from 67 dogs that were diagnosed with nasal carcinomas in 
Rakuno Gakuen University Veterinary Teaching Hospital (RGU-VTH) between April 2004 
and January 2014. The specimens were collected from dogs before treatment. The 
histopathological diagnosis of each case was evaluated and diagnosed by the veterinarians 
in the Department of Veterinary Pathology in RGU. All tissue samples were fixed in 10% 
neutral buffered formalin and embedded in paraffin. 
   The medical records of the 67 dogs were reviewed. Pretreatment clinical examinations 
including a complete blood count, serum chemistry, three-view thoracic radiographs, CT 
scans, and a fine-needle biopsy of regional lymph nodes if enlarged were performed. The 
medical records of dogs with nasal carcinomas were reviewed. Clinical staging was 
evaluated using CT imaging with Adams’ staging system (Table 1-1). 
 
(2) Immunohistochemistry staining 
   Sections of 4-μm thickness were cut from all formalin-fixed paraffin-embedded tissue 
blocks and mounted on glass slides, then were deparaffinized in xylene and rehydrated in a 
graded series ethanol. All sections were pretreated for antigen retrieval. Antigen retrieval 
was carried out by proteinase K (20 μg/ml, Dako) for 2 minutes or by autoclave at 121 ºC 
for 15 minutes with 0.1 M citrate buffer (pH 6.0). Endogenous peroxidase activity was 
blocked by rinsing for 10 minutes with 3% hydrogen peroxide (H2O2) and then nonspecific 
binding was blocked with 1% horse serum in phosphate-buffered saline (PBS: NaCl 80 g, 
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KCl 2 g, Na2HPO4 14.4 g and KH2PO4 2.4 g dissolving in 10 L distilled water) for 20 
minutes. The sections were then incubated with a primary antibody against Ki-67, survivin, 
EGFR, VEGF, and COX-2. Information on primary antibodies including clonality, dilution 
and incubation time is summarized in Table 2-1. The sections were subsequently incubated 
with a secondary antibody and then with an avidin-biotin complex solution 
(VECTASTAIN® ABC Kit, Vector Labs) for 30 minutes each at room temperature. 
3-3’-diaminobenzidine (DAB, Kanto Chemical Co.) solution was used for color 
development, and Mayer’s hematoxylin was used for counterstaining. Negative control data 
were obtained by replacing the primary antibodies with PBS. 
  
(3) Immunohistochemistry scoring  
   The Ki-67 index was determined as the percentage of Ki-67-positive tumor cells in a 
total of 1000 tumor cells. A low expression of Ki-67 was defined as a Ki-67 index below 
25%; a high expression was defined as a Ki-67 index above 25%. 
   After immunostaining the proteins survivin, EGFR, VEGF and COX-2, scoring of the 
Incubation Antigen retrieval
time (h) method
Ki-67 Monoclonal MIB-1 Mouse IgG Dako 1:100 1 Pressurized heating
 (121ºC, 15 min)
Survivin Polyclonal NB500-201 Rabbit IgG Novus Biological 1:600 16 Pressurized heating
 (121ºC, 15 min)
EGFR Monoclonal 31G7 Mouse IgG Invitrogen 1:50 16 Proteinase K
 (20µg/ml, 2 min)
VEGF Polyclonal A-20 Rabbit IgG Santa Cruz 1:100 16 Pressurized heating
 (121ºC, 15 min)
COX-2 Monoclonal 33 Mouse IgG  BD Transduction Lab 1:50 16 Pressurized heating
 (121ºC, 15 min)
PE =
Table 2-1. Primary antibodies and staining conditions
Antibody Clonality Isotype Supplier Dilution
SF =
( number of surviving colonies )
( number of cells seeded onto that plate )
( PE of treated sam le )
( PE of control sample )
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labeling was performed to estimate the degree of the protein expression in tumor tissues. A 
semi-quantitative immunohistochemical scoring system was applied similar to those 
previous reports [6, 83, 111]. An IHC score of protein was based on the percentage of 
positive labeling tumor cells and their average intensity. Percentage of positive labeling 
tumor cells was assessed at ×200 magnification and the score was given an average of 5 
fields. Scoring of percentage of positive labeling tumor cells for each protein is summarized 
in Table 2-2. The intensity of labeling tumor cells was estimated for the whole section when 
viewed at ×400 magnification. Intensity was graded as 0 for no immunostaining, 1 for weak 
immunostaining, 2 for moderate immunostaining and 3 for strong immunostaining. The 
total IHC score was calculated by multiplying the scores for the percentage and intensity, it 
obtained a total score of 0 to 12. Tumor samples with an IHC score at least 2 were defined 
as positive. An IHC score of 3 was defined as the threshold of the survivin level that 
separated tumors with high expression from those with low expression. The threshold of 
IHC scores for EGFR, VEGF and COX-2 staining were 4, 6 and 4, respectively. 
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   A rate of survivin expression ≥ 25% in the nucleus was considered nuclear positive, and 
an expression rate of < 25% was considered nuclear negative; a rate of survivin expression 
≥ 25% in the cytoplasm was considered cytoplasmic positive, and an expression rate of < 
25% was considered cytoplasmic negative.  
 
(4) TUNEL assay and assessment of apoptotic index 
   A TUNEL assay was carried out using an ApopTag® Peroxidase In Situ Apoptosis 
Detection Kit (S7100, Chemicon Merck Millipore) to detect spontaneous apoptotic cells in 
the 47 samples that taken from the dogs before receiving radiation therapy. All section 
samples were sliced, deparaffinized and rehydrated with the same way in the IHC staining. 
The samples were pretreated with proteinase K (20 μg/ml, Dako) for 10 minutes at room 
temperature. Endogenous peroxidase activity was blocked by rinsing with 3% H2O2. 
Equilibration buffer was used to cover the slide for 15 seconds, and then working-strength 
TdT solution was added; the slide was then incubated in a humidified chamber at 37 ºC for 
1 hour. The reaction was stopped by addition of working-strength Wash/Stop buffer for 10 
minutes. Anti-digoxigenin peroxidase was applied and the sections were then incubated for 
30 minutes at room temperature. DAB solution and Mayer’s hematoxylin was used for color 
development and counterstaining. A canine lymphoma tissue section was used as a positive 
control.  
   Apoptotic-positive tumor cells in a total of 1000 tumor cells were counted by 
microscopic examination in ×1000 magnification fields as the apoptotic index (AI). A low 
AI was defined as an AI at and below 0.3%; a high AI was defined as an AI above 0.3%. 
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(5) Radiation therapy and response assessment 
   Radiation therapy and the assessment of response for treatment were carried out as 
described in Chapter I.  
 
(6) Statistical analysis 
   Statistical significance of differences was analyzed with chi-squared (χ2) test for the 
relationship between the tumor markers and clinical features. Both spearman’s correlation 
method and chi-squared test were used to analyze the correlation among these tumor 
markers. The overall survival time of a patient was calculated from the starting date of 
radiation therapy to the time of death or the last follow-up. The progression-free survival 
(PFS) was defined from the starting date of radiation therapy to the day of disease 
progression or the last follow-up. The correlation between the survival and prognostic 
factors was estimated using Kaplan-Meier curves, and statistical differences between 
survival curves were calculated using a log-rank method. P values of < 0.05 were 
considered statistical significant. The commercial software StatMate III (ATMS Co., Ltd.) 
was used to perform the statistical analysis. 
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3. RESULTS 
 
(1) Immunohistochemical characterization in canine nasal carcinomas 
   The information of 67 dogs is summarized in Table 2-3. The mean and median ages for 
sampled dogs were 11.1 years and 11 years (range from 7 to 16 years of age), respectively. 
There were 11 intact females, 25 spayed females, 15 intact males and 16 neutered males. 
There were 56 pure-breed dogs and 11 mixed breed dogs. Golden retriever (n = 10), 
Pembroke Welsh corgi (n = 9) and miniature dachshund (n = 7) were the most three 
pure-breeds. Tumor samples were consisted of 29 ADCs, 17 CAs, 12 SCCs and 9 TCCs. 
Samples from all 67 dogs were evaluated for expression of Ki-67, survivin, EGFR, VEGF, 
COX-2, and AI. 
 
1) Ki-67 expression 
   Ki-67 expresses strongly in the nucleus (Figure 2-1). The percentage of Ki-67-positive 
tumor cells in all samples ranged from 0.8 to 92.3%. The median and mean Ki-67 index was 
28.5% and 34.1%. The mean Ki-67 index for ADC, CA, SCC and TCC was 29.2%, 38.2%, 
36.3% and 39.3%, respectively. Low Ki-67 expression (Ki-67 index < 25%) was observed 
in 32 samples, whereas high Ki-67 expression (Ki-67 index > 25%) was observed in 35 
samples. 
 
2) Survivin expression 
   Survivin staining was localized in the nucleus and/or cytoplasm of tumor cells (Figure 
2-2). Forty samples (59.7%) were survivin positive in the nucleus, and 48 samples (71.6%) 
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were positive in the cytoplasm. In addition, 60 samples (89.6%) were positive for survivin 
in the nucleus or cytoplasm or both. The relationship between nasal tumor types and 
survivin expression location is shown in Table 2-4. Twenty-five of the 29 ADC (25/29), 
fifteen of the 17 CA (15/17), all of the 12 SCC (12/12), and eight of the 9 TCC (8/9) were 
positive expression in survivin. The total IHC score for survivin expression ranged from 0 
to 12. The median and mean for the total survivin IHC score were 4 and 5.5. The mean 
survivin IHC score for ADC, CA, SCC and TCC was 5.5, 5.4, 5.9 and 5, respectively. Low 
survivin expression (survivin IHC score ≤ 3) was observed in 27 samples, whereas high 
survivin expression (survivin IHC score > 3) in 40 samples. 
 
3) EGFR expression 
   EGFR staining was predominantly membranous and occasionally cytoplasmic (Figure 
2-3). Fifty-nine samples (88.1%) were positive for EGFR expression. In addition, 24 of the 
29 ADC (24/29), fourteen of the 17 CA (14/17), all of the 12 SCC (12/12), and all of the 9 
TCC (9/9) were positive expression in EGFR. The total IHC score for EGFR expression 
ranged from 0 to 12. The median and mean for the total EGFR IHC score were 6 and 6.9. 
The mean EGFR IHC score for ADC, CA, SCC and TCC was 5.7, 6.3, 9.9 and 8.2, 
respectively. Low EGFR expression (EGFR IHC score ≤ 4) was observed in 20 samples, 
whereas high EGFR expression (EGFR IHC score > 4) was observed in 47 samples. 
 
4) VEGF expression 
   VEGF staining was observed in cytoplasm and membrane of tumor cells (Figure 2-4). 
Sixty-five samples (97%) were positive for VEGF expression. In addition, all of the 29 
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ADC (29/29), sixteen of the 17 CA (16/17), eleven of the 12 SCC (11/12), and all of the 9 
TCC (9/9) were positive expression in VEGF. The total IHC score for VEGF expression 
ranged from 0 to 12. The median and mean for the total VEGF IHC score were 8 and 8.1. 
The mean VEGF IHC score for ADC, CA, SCC and TCC was 8.3, 7.8, 7.4 and 9.3, 
respectively. Low VEGF expression (VEGF IHC score ≤ 6) was observed in 21 samples, 
whereas high VEGF expression (VEGF IHC score > 6) was observed in 46 samples. 
 
5) COX-2 expression 
   COX-2 staining was predominantly cytoplasmic and perinuclear region (Figure 2-5). 
Fifty-five samples (82.1%) were positive for COX-2 expression. In addition, 24 of the 29 
ADC (24/29), thirteen of the 17 CA (13/17), ten of the 12 SCC (10/12), and eight of the 9 
TCC (8/9) were positive expression in COX-2. The total IHC score for COX-2 expression 
ranged from 0 to 12. The median and mean for the total COX-2 IHC score were 6 and 5.3. 
The mean EGFR IHC score for ADC, CA, SCC and TCC was 4.7, 5.6, 6.1 and 5.7, 
respectively. Low COX-2 expression (COX-2 IHC score ≤ 4) was observed in 32 samples, 
whereas high COX-2 expression (COX-2 IHC score > 4) was observed in 35 samples. 
 
6) Apoptotic index (TUNEL assay) 
   TUNEL assays were performed for detecting apoptotic index (AI) in 47 
paraffin-embedded samples. AI was ranged from 0 to 1.2% in all samples. Mean and 
median of AI was 0.31% and 0.3%. Low-AI (AI ≤ 0.3%) was observed in 27 samples, 
whereas high-AI (AI > 0.3%) was observed in 20 samples. 
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7) Association among the expression of Ki-67, survivin, EGFR, VEGF, COX-2 and AI in 
canine nasal carcinomas 
   Using chi-squared method, significant associations between the rate of Ki-67 and EGFR 
expression, survivin expression and AI were observed. In spearman’s correlation method, 
significant correlations were found between EGFR score and Ki-67 rate, EGFR score and 
survivin score, AI and Ki-67 rate, as well AI and survivin score (Table 2-5). 
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Figure 2-1. Examples of immunohistochemical staining of Ki-67 in canine nasal carcinoma. 
(A) Squamous cell carcinoma, Ki-67 positive rate was 17.6%. (B) Adenocarcinoma, Ki-67 
positive rate was 36.2%. (C) Undifferentiated carcinoma, Ki-67 positive rate was 72.7%. 
(Original magnification ×100) 
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Figure 2-2. Examples of immunohistochemical staining of survivin in canine nasal 
carcinoma. (A) Adenocarcinoma, nuclear and cytoplasmic expression, IHC score of 12. (B) 
Squamous cell carcinoma, nuclear expression, IHC score of 12. (C) Adenocarcinoma, 
cytoplasmic expression, IHC score of 12. (D) Undifferentiated carcinoma, nuclear and 
cytoplasmic expression, IHC score of 8. (E) Squamous cell carcinoma, nuclear expression, 
IHC score of 2. (F) Adenocarcinoma, negative expression, IHC score of 0. (Original 
magnification ×400) 
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Figure 2-3. Examples of immunohistochemical staining of EGFR in canine nasal carcinoma. 
(A) Adenocarcinoma, IHC score of 12. (B) Undifferentiated carcinoma, IHC score of 12. (C) 
Squamous cell carcinoma, IHC score of 12. (D) Transitional cell carcinoma, IHC score of 8. 
(E) Squamous cell carcinoma, IHC score of 6. (F) Adenocarcinoma, IHC score of 1. 
(Original magnification ×400) 
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Figure 2-4. Examples of immunohistochemical staining of VEGF in canine nasal 
carcinoma. (A) Adenocarcinoma, IHC score of 12. (B) Squamous cell carcinoma, IHC score 
of 12. (C) Squamous cell carcinoma, IHC score of 12. (D) Adenocarcinoma, IHC score of 8. 
(E) Squamous cell carcinoma, IHC score of 4. (F) Transitional cell carcinoma, IHC score of 
2. (Original magnification ×200) 
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Figure 2-5. Examples of immunohistochemical staining of COX-2 in canine nasal 
carcinoma. (A) Undifferentiated carcinoma, IHC score of 12. (B) Squamous cell carcinoma 
IHC score of 8. (C) Adenocarcinoma, IHC score of 4. (D) Transitional cell carcinoma, IHC 
score of 6. (E) Adenocarcinoma, IHC score of 6. (F) Undifferentiated carcinoma, IHC score 
of 2. (Original magnification ×200) 
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(2) Association between expression of tumor markers and clinical features in dogs with 
nasal carcinoma 
   Regarding the T stage of 67 dogs, there were 12 dogs (17.9%) with T1 disease, 5 dogs 
(7.5%) with T2 disease, 17 dogs (25.4%) with T3 disease, and 33 dogs (45.2%) with T4 
disease. Cribriform plate destruction was detected on CT images in 33 dogs.  
   Ki-67 expression was significantly associated with the T stage. High-Ki-67 expression 
was significantly associated with advanced-tumor dog (T3+T4) (P = 0.029). High-Ki-67 
expression was also significantly correlated with the dogs with cribriform plate destruction 
(P = 0.020). No significant association between Ki-67 expression and sex or age was 
observed (Table 2-6a).  
   Survivin expression was significantly correlated with the T stage. High expression of 
survivin was associated with advanced-tumor (T3+T4) dog significantly (P = 0.018). No 
significant association between survivin expression and cribriform plate destruction, sex or 
age was observed (Table 2-6a). 
   EGFR expression was not highly associated with the clinical findings, including T stage, 
cribriform plate destruction, sex or age (Table 2-6b).  
   VEGF expression was significantly associated with the T stage. High VEGF expression 
was highly correlated with advanced-tumor dog (T3+T4) (P = 0.026). No significant 
association between VEGF expression and cribriform plate destruction, sex or age was 
observed (Table 2-6b). 
   COX-2 expression was not closely related with the clinical features, which included T 
stage, cribriform plate destruction, sex or age (Table 2-6b). 
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(3) Association between expression of tumor markers and the response to RT in dogs with 
nasal carcinoma 
    Forty-seven dogs received radiation therapy for treatment. There were 22 dogs with 
ADC, 13 dogs with CA, 9 dogs with SCC and 3 dogs with TCC. The mean and median ages 
for sampled dogs were 11.2 years and 11 years (ranged from 7 to 16 years of age), 
respectively. There were 9 intact females, 19 spayed females, 10 intact males and 9 neutered 
males. There were 41 pure-breed dogs and 6 mixed breed dogs. Golden retriever (n = 9) and 
Pembroke Welsh corgi (n = 8) were the most two pure-breeds. Of 47 dogs, 43 dogs were 
able to evaluate the response of radiation therapy. Twenty-six dogs were determined to have 
partial response (PR) (14 ADC, 10 CA, 1 SCC, 1 TCC), and seventeen dogs had a stable 
disease (SD) in response to radiation therapy (6 ADC, 2 CA, 8 SCC, 1 TCC).     
   Analyzing the associations between the markers and treatment response, only survivin 
expression was significantly associated with the response to RT (P = 0.039). Regarding 
Ki-67, EGFR, VEGF and COX-2 expression, no significant associations were observed 
between the response of treatment and these markers (Table 2-7). TUNEL assay resulted 
that the group of PR samples had significantly higher AI than the group of SD samples did 
(mean ± SD of the AI: 0.38 ± 0.25% versus 0.23 ± 0.19%; P = 0.036). 
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(4) Correlation between expression of tumor markers and survival in dogs with nasal 
carcinoma treated with RT 
   To investigate the correlation between protein expression and clinical outcome, PFS or 
overall survival times were compared between the low and high expression groups of the 47 
nasal carcinoma dogs. The median of PFSs and survival times are summarized in Table 2-8. 
High-Ki-67 dogs were highly related with shorter PFS in nasal carcinomas (Median PFS of 
124 days versus 236 days; P = 0.037) but no significant correlation was observed between 
PFSs and expression of survivin, EGFR, VEGF, COX-2 or AI. Dogs with a high-Ki-67 
revealed significantly shorter survival times than that with a low-Ki-67 (P = 0.004), with 
MST of 150 days and 261 days, respectively. The respective MSTs for high-survivin and 
low-survivin dogs were 176 days and 261 days, the difference was significant (P = 0.042). 
The dogs with a low expression for EGFR had a better survival time than the dogs with a 
high EGFR expression (MST of 275 days versus 176 days; P = 0.006). However, neither 
expression of VEGF nor COX-2 in canine nasal carcinoma was found significant 
correlation with survival times after radiation therapy (246 days versus 187 days for VEGF; 
236 days versus 255 days for COX-2). High-AI dogs were tended to relate with longer MST 
in nasal carcinomas but it was insignificant (Median MST of 249 days versus 176 days; P = 
0.076). 
  
 59 
 
 
 
 
  
 60 
4. DISCUSSION 
 
   IHC staining has not been widely used to predict the outcome to radiation therapy in 
veterinary medicine. Only two reports have been published recently [6, 61]. Therefore one 
aim of this chapter was to assess the outcome of radiation therapy using IHC. 
   Ki-67 is a proliferation marker generally used to assess malignancy and prognosis in 
several tumors in both humans and dogs [7, 67, 81, 88]. High-Ki-67 tumors have been 
considered malignant and aggressive in previous human NPC studies [106, 112]. A 
significant correlation was found between Ki-67 expression and clinical T stage in dogs 
with nasal carcinoma. High level of Ki-67 was correlated with the advanced-stage tumor 
(T3+T4), cribriform plate destruction and shorter survivals after radiation therapy. Highly 
proliferative tumors showed aggressive behaviors in canine nasal carcinomas. Regarding 
Ki-67 and tumor radiosensitivity, low levels of Ki-67 have been believed to reflect hypoxia 
and radioresistance. This is because in a hypoxic environment, cells are preferentially in the 
G0 phase, the most radioresistant phase of the cell cycle [43]. Oral and laryngeal cancers in 
humans with a high-Ki-67 tend to respond better to radiation therapy than those with a 
low-Ki-67 [19, 24, 49]. In cats with squamous cell carcinomas that were treated with 
electron beam radiation therapy, high-Ki-67 cats were found to have a longer disease-free 
interval [61]. However, no significant difference was observed in Ki-67 expression level 
between good and poor responses to treatment in this chapter. High Ki-67 expression was 
suggested a negative prognostic significance for survival times in canine nasal carcinomas. 
   Survivin expresses in two different locations, the nucleus and the cytoplasm, in tumor 
cells. Additionally, the different locations of survivin are related to different functions [41, 
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111]. Expression of survivin in the nucleus is associated with cell proliferation. Expression 
in the cytoplasm however, is correlated with apoptosis inhibition and the control of cellular 
survival. Survivin binds to the microtubules of the mitotic spindle during the G2/M phase of 
the cell cycle in the nucleus. Survivin inhibits apoptosis via either a direct blockage of 
caspase-3, -7 and -9 or by indirectly blocking activity of the pro-apoptotic protein 
Smac/DIABLO, preventing binding to other IAPs such as XIAP in the cytoplasm [41]. In 
our study, 59.7% of the dogs with nasal carcinomas were found to be positive for the 
expression of nuclear survivin, and 71.4% of the dogs were positive for cytoplasmic 
survivin. However neither nuclear expression of survivin nor cytoplasmic expression of 
survivin was found to have any association with survival time in the 47 dogs with nasal 
carcinoma treated with a radiation therapy. High IHC score of survivin was observed in the 
advanced clinical stage and poor response to radiation in dogs with nasal carcinoma. 
Therefore, survivin overexpression is strongly suggested to be an unfavorable prognostic 
factor for predicting the outcome of treatment with radiation.  
   EGFR is a transmembrane protein of receptor tyrosine kinase. Being activated the 
downstream of signal transduction cascade, EGFR play an important role in tumor 
proliferation, angiogenesis, differentiation, and survival [18, 25]. In canine nasal carcinomas, 
EGFR expression was not significantly associated with the clinical T stage or cribriform 
plate destruction. Moreover, EGFR trended to show a relationship with the treatment 
response in the 43 dogs that treated with radiation therapy despite its insignificance. 
Overexpression of EGFR has been reported to have negative prognosis for survival in 
several tumors in human and veterinary studies [7, 25, 70, 79]. Our results suggested that 
high-EGFR dogs showed significantly shorter overall survival than low-EGFR dogs (MST: 
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176 days versus 275 days). A shorter PFS was also observed in high-EGFR dogs but it was 
not significant (151 days versus 250 days; P = 0.064). 88.1% of 67 canine nasal carcinoma 
samples were tested positive for EGFR expression in our results. Only one report that 
published previously from Shiomitsu et al. was about the EGFR expression in 24 dogs with 
nasal carcinomas. Although the positive rate in our study was higher than that in the 
previous report (54.2%) performed a same IHC scoring, the mean EGFR IHC score was 
similar [83]. 
   In this study, 97% of canine nasal carcinoma samples were found to be positive for 
VEGF staining. VEGF is produced by tumors to stimulate endothelial migration and 
proliferation. There was a significant correlation between increased microvessel count and 
VEGF expression [29, 100]. Hypoxia is a regulator of VEGF expression in NPC cells [92]. 
Expression of VEGF in NPC tumor biopsy samples has been associated with hypoxia 
markers (e.g. HIF-1α) expression, and with poor outcome post radiation therapy [35]. 
Overexpression of VEGF was significantly correlated with advanced clinical stage, local 
recurrence and distant metastasis. This also showed poor survival rate in NPC [55, 100]. A 
significant association was found between high-VEGF dogs and advanced-tumor dogs 
(T3+T4) in nasal carcinoma. When a tumor grows, an adequate blood supply is necessary. It 
is possible to produce VEGF to stimulate vascular formation in a high-stage tumor in canine 
nasal carcinomas. 
   In previous studies, a high percentage (71-90%) of canine nasal carcinomas have been 
reported to express COX-2 [6, 13, 36, 45]. Similarly, positive staining for COX-2 was 
expressed in 82.1% of canine nasal carcinomas in this chapter results. COX-2 is a key 
enzyme of prostaglandin synthesis, which has been related to apoptosis inhibition, 
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metastasis and angiogenesis in tumors [21, 69, 91]. An association has been observed 
between COX-2 expression and prognosis in NPC [17, 44, 70]. However, only few reports 
have documented an association between COX-2 expression and prognosis in dogs with 
cancers [21]. One report currently published by Belshaw et al. that no association was found 
between COX-2 expression and survival in dogs with nasal carcinomas treated with a 
hypofractionated radiation therapy [6]. The expression of COX-2 was not associated with 
the clinical variables including T stages (T3+T4 versus T1+T2), presence of cribriform plate 
destruction, treatment response or survivals in our results. Even though the role of COX-2 
in carcinogenesis appears clear, the prognostic significance of COX-2 expression in canine 
cancer has not been clearly established. COX-2 expression as measured by IHC might not 
be indicative of the actual enzymatic activity [21].  
   The relationship between apoptosis and the outcome of radiation has been studied in 
several cancers in human. High level of apoptosis has a strong association with good 
outcome in patients that treated with radiation therapy [3, 77, 102]. In our study, the dogs 
with a good response to radiation therapy appeared to have a higher AI (P = 0.036), 
although longer survival was not found statistically (P = 0.079). Small biopsy sample that is 
taken from a large tumor is not a good representation of the whole tumor. This is due to the 
fact that specimen may come from areas that is highly apoptotic or low. It has also been 
suggested in previous studies [6, 19]. 
   Most canine nasal carcinomas were overexpressed survivin (89.6%), EGFR (88.1%), 
VEGF (97%), and COX-2 (82.1%) in the results. Study of the radiation therapy efficacy 
combined with molecular inhibitors in veterinary medicine is needed, especially in 
advanced-stage tumors and those that often have a poor response to radiation therapy.  
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5. SUMMARY 
 
   Immunohistochemistry is simple to perform and to evaluate. It is also cheap, fast, and 
can be used readily on the same small biopsies that are used to evaluate canine nasal 
carcinomas.  
   A significant correlation was found between Ki-67 expression and clinical T stage in 
dogs with nasal carcinoma. High Ki-67 was closely correlated with aggressive tumor. 
Moreover, high-Ki67 dogs were observed to have shorter survival and progression-free 
survival after treating with radiation.  
   Overexpression of survivin was observed in the advanced clinical stage, poor response 
to radiation and shorter survival after radiation treatment. Therefore, survivin is strongly 
suggested a valuable prognostic factor for predicting the outcome of treatment with 
radiation in canine nasal carcinomas. 
   EGFR expression was not closely correlated with the clinical T stage or presence of 
cribriform plate destruction. Although EGFR trended to show a relationship with the 
treatment response in the 43 dogs that treated with radiation, it was not significant. However, 
high-EGFR dogs showed significantly shorter overall survival than low-EGFR dogs. 
   High-VEGF dogs were strongly associated with an advanced-stage in nasal carcinomas 
but they were not related with survivals. On the other hand, COX-2 expression was not 
associated with the clinical features, treatment response and even survivals in our results. 
   Survivin, EGFR, VEGF and COX-2 were detected in 60 (89.6%), 59 (88.1%), 65 (97%) 
and 55 (82.1%) canine nasal carcinoma samples, respectively. It is also important to search 
valuable biomarkers involving canine nasal carcinomas for therapeutic targets that may lead 
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to more effective treatment of dogs with nasal carcinoma. We would evaluate the 
radiosensitizing effect of molecular targeted agents in a nasal SCC cell line in the next 
chapter. 
 
 
Part of this chapter was published as “Fu, D.R., Kato, D., Watabe, A., Endo, Y. and 
Kadosawa, T. 2014. Prognostic utility of apoptosis index, Ki-67 and survivin expression 
in dogs with nasal carcinoma treated with orthovoltage radiation therapy. J. Vet. Med. 
Sci. 76: 1505-1512.”  
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CHAPTER III. 
 
 
Establishment and characterization of a canine nasal squamous cell 
carcinoma cell line, and radiosensitizing effect in the cell line 
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1. INTRODUCTION 
 
   Radiation therapy has become increasingly available and in demand in companion 
animals with cancers. Recently, there has been an increase in information about its 
effectiveness in the treatment of a number of different tumor types [59, 60]. Canine nasal 
tumors are considered one of tumor types usually treated with radiation therapy [1, 50, 68, 
97]. Nasal squamous cell carcinoma showed a worse response rate comparing the other 
nasal carcinomas in Chapter I. Squamous cell carcinomas were clinically suggested a 
radioresistant nasal tumor type. Hence, it is important to grasp the mechanisms of 
radioresistance to develop more specific treatment for canine nasal tumor and improve 
patient prognosis.  
   The establishment of growing cell lines from solid tumors provides a useful tool for 
research on various facets of tumor cell biology [95]. Canine tumor cell lines have been 
used to characterize the tumor cells [5, 37, 63] and to investigate novel therapy in vitro and 
in vivo [38, 105]. In spite of this usefulness of cell lines, few canine squamous cell 
carcinoma cell line has been developed previously.  
   The mechanisms of cellular malignant transformation include the regulation of signal 
transduction, cell differentiation, apoptosis, DNA repair, cell cycle progression, and 
angiogenesis. Applications of molecular radiobiology in recent years have altered the 
understanding of tumor radioresistance and the cellular response to ionizing radiation [22, 
57, 109]. Immunohistochemical expression of survivin, EGFR, VEGF and COX-2 in nasal 
carcinomas was investigated in Chapter II. Most canine nasal carcinoma tissues were 
overexpressed these molecular biomarkers. The result of Chapter II showed that 
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overexpression of survivin was closely associated with poor prognosis for radiation therapy. 
Moreover, it was also correlated with the sensitivity to radiation treatment for dogs with 
nasal carcinoma. Enhancing radiosensitivity of the tumor cells would be an optimal strategy 
for improving tumor response to radiation therapy [84]. Several biological agents designed 
to target the molecular progresses have shown both radiosensitizing effects and 
antiproliferative activities in preclinical models of human cancers [14, 30, 39,101, 105, 
110]. 
   Currently, survivin is considered to be a new target for cancer therapy. YM155, a small 
imidazolium-based compound, was identified a suppressant of survivin. It specifically 
inhibits the survivin expression of both the mRNA and protein levels and exhibits antitumor 
activity in preclinical models [65, 104]. Single agent of survivin inhibition has been found 
to induce apoptosis in tumor cells and in combination with a chemotherapeutic agent, which 
can enhance the chemotherapeutic effect in human cancers [40, 104]. YM155 also showed 
to enhance the radiosensitivity of tumor cells in vitro and in vivo studies [39, 72]. 
   Moreover, celecoxib, a COX-2-selective inhibitor, is a non-steroidal anti-inflammatory 
drug that has been shown to enhance tumour radiosensitivity in human cancer cell lines, 
such as NPC, oral SCC and cervical cancers [17, 96, 101, 110]. Toceranib phosphate 
(Palladia®) is a tyrosine kinase inhibitor (TKI) targeting the VEGFR-2, PDGFR, Kit, and 
Flt-3. It has demonstrated encouraging single-agent antitumor activity against canine MCT. 
Toceranib has also been used in canine nasal tumors and frontal sinus SCCs [56, 99]. Some 
information indicates synergy between the related TKI sunitinib and radiation therapy in 
human preclinical models. Sunitinib is thought to enhance radiation-induced endothelial 
damage by inhibition of the PI3K/Akt signaling pathway, which then leads to apoptosis [14, 
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20]. Gefitinib is an EGFR inhibitor, which interrupt the signaling pathway of EGFR. 
Gefitinib has enhanced radiosensitivity of human lung cancer cells by inhibiting the 
activation of the anti-apoptotic and proliferative signal transduction pathways [80]. 
   In Chapter III, we established a cell line of canine nasal squamous cell carcinoma and a 
radioresistant subclone cell line. This chapter then compared the differences between the 
radiosensitive and radioresistant cell line. Additionally, according to the protein expression 
in canine nasal carcinomas in the results of Chapter II, we also attempted to evaluate the 
radiosensitizing effect of molecular targeted therapeutic agents in the nasal SCC cell line. 
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2. MATERIALS AND METHODS 
 
(1) Establishment of a cell line and culture 
   A biopsy of the primary tumor, located in the nasal cavity, was obtained from a 
6-year-old neutered female miniature Schnauzer via a plastic cannula at the Oncology 
Service in Rakuno Gakuen University Veterinary Teaching Hospital (RGU-VTH). Fresh 
tissue samples from the mass of the nasal cavity were used for primary culture, and the 
remaining tissues were fixed with 10% neutral buffered formalin for histopathology. The 
neoplastic mass was diagnosed as a squamous cell carcinoma (SCC). 
   The tumor tissues were washed with sterile PBS and cut into 1-mm3 fragments. The 
fragments were placed into a 100-mm sterile tissue culture dish (TRP) containing 10 ml of 
RPMI-1640 medium (Sigma) supplemented with 2 mM L-glutamine, 10% heat-inactivated 
fetal bovine serum (FBS) (Sigma) and antibiotics (50 IU/ml penicillin and 50 μg/ml 
streptomycin, Sigma). The culture dish was maintained at 37°C humidified atmosphere of 
5% carbon dioxide (CO2) in air. The primary cultured cells were observed every day for any 
changes.  
   Cells were allowed to grow to 80% confluence for subsequent passages, and 
sub-cultured every week. When cells reached confluent, the media was aspirated and cells 
were washed with PBS solution once, and 1 ml 0.25% trypsin-EDTA (Gibco) was then 
added to culture dishes for a few minutes. Detached cells were resuspended and 1×105 of 
cells were plated in cell culture dish with 10 ml refreshed medium and incubated at 37°C 
with 5% CO2 and 95% air. The cell line, named as CNSC1, was maintained in tissue culture 
for 20 passages over 6 months. Experiments were carried out with the CNSC1 cells between 
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20-30 passages.  
 
(2) Evaluation of tumor growth in xenotransplantation   
   Three 6 week-old male athymic nude mice (BALB/cAJc l-nu (nu/nu), Sankyo Lab 
Service Co. Sapporo) were used for the xenotransplantation. Mice were housed 3-5 per cage, 
exposed to 12-hour light dark cycles, and given free access to sterilized pelleted food (FR-1, 
Funabasi Farm Co.) and sterilized water. 
   Before transplantaion, the mice were irradiated with a dose of 4 Gy of X-rays using an 
orthovoltage X-ray machine (TITAN-450S, GE) at 450 KV/10 mA 60 cm X-ray 
source-cells distance at an exposure rate of 1.96 Gy/min with a filter of 1.0 mm of Al, 0.3 
mm of Cu and 0.5 mm of Sn. After 7 days of irradiation, CNSC1 cells (2×106 cells 
resuspended in 0.3 ml of medium) were injected subcutaneously into the right hind leg 
region of the mice. The size of mass was measured by a caliper and recorded every 5 to 7 
days. Tumor volume was calculated from measurement of tumor length (L) and width (W) 
according to the formula of 0.5×L×W2. After 8 weeks of transplantation, the mice were 
killed humanely, and the masses were removed and fixed in 10% neutral buffered formalin 
for histology. The protocol of experimental animal study was approved by, and in 
accordance with, the institutional guidelines established by Experimental Animal Ethics 
Committee, Rakuno Gakuen University. 
 
(3) Establishment of radioresistant CNSC1 subclone cell line 
   CNSC1 cells were seeded in 100-mm culture dish with a density of 1x105 cells/dish in 
medium. Cell line was cultured in a 37°C humidified 5% CO2 incubator. CNSC1 subclone 
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cell line was established with treating 4 rounds of sublethal ionizing irradiation (12 Gy) by 
use of an orthovoltage X-ray machine (TITAN-450S, GE) at 200 KV/20 mA 40 cm X-ray 
source-cells distance at an exposure rate of 2.87 Gy/min with a filter of 2.0 mm of Al. After 
treatment, the surviving cells were selected and cultured to produce the next generation of 
the subclone cells. Finishing four rounds of irradiation, the subclone CNSC1 cells were 
produced, and were defined as a radioresistant subclone cell line and named for CNSC1-IR. 
Experiments were performed with the CNSC1-IR cells within 10 passages after irradiation. 
The procedures of established radioresistant subclone cell lines were reported in some 
published articles [22, 109]. 
 
(4) Clonogenic survival assay 
   Radiosensitivity was measured by a clonogenic survival assay following exposure to 
irradiation. Cells were seeded in 6-well culture plates (400-2,000 cells/well) for 1 hour and 
were exposed to radiation doses of 0, 2, 4, 6 and 8 Gy. A 5-cm water-dense pad was placed 
underneath the plates to absorb X-ray backscatter. Control cells (radiation dose of 0 Gy) 
were transported along with the other treated cells but remained outside the radiation room 
during treatments. All cells were returned to the incubator, and the medium was completely 
changed weekly. The cells were remained in the incubator until the colonies had grown to a 
size that was sufficient for counting without convergence. The cells were cultured for 7 to 
10 days. At the time of counting, each plate was rinsed with PBS, fixed with 70% ethanol, 
and stained with Wright-Giemsa stain. The surviving colonies were defined as a colony 
composing 50 or more cells, and the numbers of surviving colonies were recorded. For each 
of the 3 wells in given cell line. The experiments were performed 3 times, yielding 9 
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samples for each cell line at each irradiation dose. 
   Plating efficiency (PE) was calculated as the numbers of colonies the numbers of cells 
seeded for each plate. The formula for PE is as follows: 
PE = 
( number of surviving colonies ) 
( number of cells seeded onto that plate ) 
 
   Survival fraction (SF) was calculated as t divided by treated sample divided by the PE 
of control sample. The formula for SF is as follow:  
SF = 
( PE of treated sample ) 
( PE of control sample ) 
  
(5) Cell growth analysis in response to radiation 
   CNSC1 and CNSC1-IR cells were seeded into a 24-well culture plate (1×104 cells/well). 
After incubation of 18 hours, the cells were treated with or without irradiation of a 6 Gy. Cells 
growth was monitored and counted at every 24 hour-interval. Cells were collected with 
trypsinization (0.25% trypsin-EDTA) and centrifugation, were then resuspended in 
RPMI-1640 and the numbers of survival cells were measured with trypan blue exclusion 
assay. Trypan blue exclusion assay was applied to distinguish survival and dead cells (dead 
cells stain dark blue). A cell suspension was mixed with equal volumes of trypan blue 
solution and 10 μl of the mixed sample was filled into a hemocytometer chamber and counted 
cell numbers on a ×100 field. The doubling time (DT) of CNSC1 cell line was calculated by a 
following formula: 
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DT = (T2 − T1) log2 / (log N2 − log N1) 
T1, T2: The time from cell seeding  
N1: The cell number at T1 
N2: The cell number at T2 
 
(6) Detection of apoptotic cells 
   The effect of X-ray irradiation and/or drugs on the induction of apoptosis was detected 
with an FITC Annexin-V/Dead cell apoptosis kit (invitrogen). Cells were collected with 
trypsinization and centrifugation. After harvested, cells were then washed with cold PBS. The 
washed cells were re-centrifuged and discarded the supernatant, and then resuspended the 
cells in 1× annexin-binding buffer. The cell density was determined to ~1×106 cells/ml, and a 
volume of 100 μl were prepared for per assay. Five μl of FITC annexin-V solution and 1 μl of 
the 100 μg/ml propidium iodide (PI) were added to each 100 μl of cell suspension, then the 
cells were incubated at room temperature for 15 minutes. After the incubation period, 
additional 400 μl of 1× annexin-binding buffer were added and mixed gently. The stained 
cells were analyzed by flow cytometry. The population is separated into three groups. Live 
cells are showed both Annexin-V and PI negative, while cells that are in apoptosis are 
Annexin-V positive and PI negative, and cells that are in late apoptosis or already dead are 
showed both Annexin-V and PI positive. 
 
(7) Immunoblot analysis 
   Western blot analysis was used to compare the level of survivin expression of CNSC1 and 
of CNSC1-IR cell lines, and assessed the effect of survivin suppressor, YM155 (Selleckchem), 
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on survivin protein in both cell lines that incubated with in the presence of various 
concentrations (10, 25, 50 and 100 nM) of YM155 for 48 hours.  
   Cells were washed twice with ice-cold PBS, then harvested and centrifuged at 4°C for 5 
minutes at 1,200 rpm. The cells were then lysed with an extraction buffer containing 50 mM 
Tris-HCl, 150 mM NaCl, 5 mM EDTA, 1% Triton-X, 0.1% sodium dodecyl sulfate (SDS), 4 
mM Pefabloc SC, 5 μg/ml Aprotinin, 5 μg/ml Leupeptin, 10 mM NaF, 2 mM Na3VO4 and 
Phos-stop. The protein concentration of lysates was measured with the BCA Protein Assay 
Reagent (Thermo).  
   Equal amounts of protein lysates (20 μg) were loaded into the wells of sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 15 % gel. Standard running buffer 
(25 mM Tris/HCl, 190 mM glycine and 0.1% SDS) was used as an electrophoresis buffer. 
The protein samples were separated at 500 V and 10 mA in about 2 hours and the separated 
proteins were then transferred to a nitrocellulose membrane with continuous buffer (40 mM 
Tris/HCl, 50 mM glycine, 0.04% SDS and 20% methanol) at 20 V and 500 mA for 45 
minutes. The membrane was blocked for 30 minutes with 5% non-fat milk and was incubated 
overnight at 4°C in primary antibody. Specific antibody from a rabbit against survivin 
(1:3,000 dilution; Novus biological) was used as the primary antibody. After washing with 
PBS-Tris, horseradish-peroxidase-labeled goat anti-rabbit IgG (1:10,000 dilution; Abcam) 
was used as the secondary antibody.  
   An ECL Plus Western Blotting Detection Reagent (GE Healthcare) was applied for 5 
minutes and the optical density of each protein band was captured using a CCD camera-based 
imager. Image analysis software was used to read the band intensity of the target proteins. 
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(8) Drugs preparation and cell growth inhibition assay 
   YM155 (Selleckchem), celecoxib (Sigma), toceranib (Pfizer) and gefitinib (Selleckchem) 
were dissolved in dimethyl sulfoxide (DMSO, Nacalai tesque) at a stock concentration of 10 
mM and stored at -80°C. Drugs were diluted in medium just before addition to cell cultures.  
   Cell growth inhibition assay were performed with or without drugs. Cells were seeded 
into 96-well plates (1200 cells/well) and then incubated in RPMI-1640, which was 
described before, for 18 hours. After the medium was changed, the cells were incubated for 
72 hours in the phenol red-free RPMI1640 (100 μl/well) with YM155 (3, 10, 30, 100, 300, 
1,000 and 3,000 nM) or celecoxib (0.1, 0.3, 1, 3, 10, 30, 100 and 300 μM) or toceranib 
phosphate (0.01, 0.03, 0.1, 0.3, 1, 3, 10 and 30 μM) or gefitinib (0.03, 0.1, 0.3, 1, 3, 10, 30 
and 100 μM). Cell growth activity was determined by a WST-8 [2-(2-methoxy- 
4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt]-  
based colorimetric assay with a Cell Counting Kit-8 (CCK-8, Dojin). CCK-8 solution (10 μl) 
was added in each well containing 100-μl of medium. The plates were incubated for further 
3 hours at 37°C. The optical density (OD) was measured at a wavelength of 450 nm with a 
microplate reader (UltramarkTM, Bio-rad Lab.). 
   Growth activity was expressed as a percentage of control absorbance values obtained in 
the absence of drug, which was calculated as (ODdrug − ODblank) / (ODvehicle − ODblank) × 
100%. The IC50 values of YM155, celecoxib, toceranib and gefitinib based on cellular 
growth activity were calculated. The IC50 value was defined as the drug concentration 
resulting in 50% of maximal growth inhibition as determined from the dose-response curve.  
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(9) Statistical analysis 
   The averages of at least 3 independent experiments were used in each independent study. 
Data were presented as means ± standard deviation and were compared between groups 
with unpaired Student’s t-test. P values of < 0.05 were considered statistically significant.  
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3. RESULTS 
 
(1) Establishment and characterization of a canine nasal squamous cell carcinoma cell 
line 
 
1) Morphology of the cell line, CNSC1 
   Canine nasal squamous cell carcinoma cell line, CNSC1, cells show a typical epithelial 
cell morphology with being polygonal to cuboidal in shape, large nuclear to cytoplasmic 
ratio (N/C ratio) and prominent nucleoli (Figure 3-1). These cells grow in a form of colonies 
on the culture disk and adherence loosely to each other. The N/C ratio is approximately 1:1. 
The nuclei commonly often have 2 to 5 large nucleoli. Binucleate cells and "giant forms" 
are visible. The nuclei and cytoplasm are filled with many tiny vesicles. The mitotic activity 
is rare. 
 
Figure 3-1. Morphology of CNSC1 cells. Cells show a typical epithelial cell morphology 
with being polygonal to cuboidal in shape, large nuclear to cytoplasmic ratio (N/C ratio) 
and prominent nucleoli. (Original magnification, Left: ×40; Right: ×200) 
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2) Growth of the xenotransplanted tumor 
   The xenotransplanted tumors grew in the right subcutis of hind leg region of nude mice. 
The growth curve of the xenotransplanted tumors was shown in Figure 3-2. 
 
3) Histological evaluation of the xenotransplanted tumor 
   Histologically, the xenotransplanted neoplasm was presented multilobular, densely 
cellular, unencapsulated and poor demarcated in the subcutis. The neoplastic mass was 
composed of plenty numbers of lobular islands, nests and packets of neoplastic epithelial 
cells with variable degree of keratinization, and also, accompanied with amounts of 
remarkably eosinophilic lamellar keratins to form “keratin pearls”. The neoplastic cells 
showed in pleomorphic shapes and varied sizes, from small basaloid to large polygonal, 
with distinct cellular borders, abundant eosinophilic cytoplasm, central vesicular nuclei and 
finely stripped nucleoli. Anisocytosis and anisokaryosis were predominant. Mitotic activity 
was moderated that ranged from 0-2 per high power field (HPF). Aggressive invasion to 
muscles and local necrosis mixed by epithelial debris and keratins were present in the 
neoplastic mass (Figure 3-2). 
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Figure 3-2. The growth curve of CNSC1 xenotransplanted tumors (top right picture) and 
the histological evaluation of CNSC1 xenotransplanted tumor (bottom pictures) 
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(2) Establishment of a radioresistant CNSC1 subclone cell line (CNSC1-IR) 
   The radioresistant CNSC1 subclone cell line, CNSC1-IR and control CNSC1 cells were 
irradiated with a range of doses of 2 to 8 Gy, and then examined through a clonogenic 
survival assay. CNSC1-IR showed decreased radiosensitivity compared with CNSC1 
(Figure 3-3a, b). The survival fraction in 2 Gy (SF2) of CNSC1 and CNSC1-IR was 60% ± 
4% and 83% ± 3%, respectively.  
   The doubling time (DT) of control CNSC1 cell line was 18.5 hours. Furthermore, 
CNSC1-IR and control CNSC1 were subjected to 6 Gy of irradiation to examine the effect 
on cell growth. As shown in Figure 3-3c, cell growth delay after 6 Gy of irradiation was less 
for CNSC1-IR than for control CNSC1. For fivefold increase in cell number, the delay was 
~72 hours for CNSC1-IR compared with ~94 hours for control CNSC1.  
   The rates of apoptotic cells were detected with an FITC Annexin-V/PI apoptosis kit for 
flow cytometry. As shown in Figure 3-3d, CNSC1-IR showed significantly decreased 
apoptosis cell rate than control CNSC1 at 24 hours, 48 hours and 72 hours post irradiation 
of 6 Gy. The above results indicated that a CNSC1-radioresistant subclone cell line 
(CNSC1-IR) was established. 
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Figure 3-3. Comparison of radiosensitivity of CNSC1 and CNSC1-IR cell line. (a, b) 
Clonogenic survival assay. CNSC1 and CNSC1-IR were irradiated with 2-8 Gy of radiation 
dose, then were counted the colonies after 7-10 days and calculated the survival fractions. 
The SF2 of CNSC1 was 60% ± 4% and SF2 of CNSC1-IR was 83% ± 3%. (c) The 
proliferation of CNSC1 and CNSC1-IR cell lines with/without irradiation of 6 Gy. Cell 
numbers were counted at different times. Cell growth delay after irradiation was less for 
CNSC1-IR than for CNSC1 cell line. (d) The apoptotic rates were detected with an FITC 
Annexin-V/PI apoptosis kit. CNSC1-IR showed significantly decreased apoptotic cell rate 
than CNSC1 at different times after irradiation (6 Gy). 
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(3) Level of survivin protein expression and radiosensitizing effect of YM155 in CNSC1 
and CNSC1-IR cells  
 
1) Expression of survivin in cell lines 
   We detected the levels of survivin protein in CNSC1 and CNSC1-IR cells via 
immunoblot analysis (Figure 3-4a). Survivin expression was examined higher in the 
radioresistant cell line, CNSC1-IR than in control CNSC1 cells. 
 
2) Inhibition of survivin expression in CNSC1 and CNSC1-IR cells by YM155 
   We examined the effect of YM155 on survivin expression in CNSC1 and CNSC1-IR 
cell lines by immunoblot analysis. CNSC1 and CNSC1-IR cells were incubated in the 
absence (control, 0.1% DMSO) or presence of various concentrations (10, 25, 50, 100 nM) 
of YM155 for 48 hours. Cell lysates were then prepared and subjected to immunblot 
analysis with an antibody to survivin. Inhibition of survivin protein level showed with a 
concentration-dependent manner (Figure 3-4b). 
 
3) Effect of YM155 on radiation-induced apoptosis in CNSC1 and CNSC1-IR cells  
   We next examined the effect of YM155 on radiation-induced apoptosis in CNSC1 and 
CNSC1-IR cells with the use of the FITC Annexin-V/PI apoptosis assay for flow cytometry. 
Combined treatment of both cell lines with YM155 and radiation (6 Gy) resulted in an 
increase in the number of apoptotic cells after a 48 hour-incubation, which was greater than 
the sum of the increase induced by YM155 or radiation alone (Figure 3-5).  
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4) Radiosensitizing effect of YM155 in CNSC1 and CNSC1-IR cells 
   We examined the radiosenistizing effect of YM155 in CNSC1 and CNSC1-IR cell lines 
by clonogenic assay. Cells were incubated with YM155 (50 nM) or a vehicle (control, 0.1% 
DMSO) for 48 hours, exposed to the radiation doses of 2 to 8 Gy, and then incubated in 
drug-free medium for 7 to 10 days for determination of colony-forming ability (Figure 3-6). 
The SF2 of CNSC1 treated with and without YM155 was 52% ± 5% and 60% ± 4%, 
respectively. And, the SF2 of CNSC1-IR treated with and without YM155 was 62% ± 2% 
and 83% ± 3%, respectively. The survival fractions for irradiation decreased in both CNSC1 
and CNSC1-IR cells that treated with YM155.  
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Figure 3-4. (a) Expression of survivin in CNSC1 and CNSC1-IR cells. Survivin expression 
was higher in the radioresistant cell line, CNSC1-IR than in the control CNSC1 cells. (b) 
Effect of YM155 on survivin expression in CNSC1 and CNSC1-IR cells. CNSC1 and 
CNSC1-IR cells were treated with a various concentration of YM155 for 48 hours.  
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Figure 3-5. Apoptotic rate of CNSC1 and CNSC1-IR cells treated with an irradiation of 6 
Gy or YM155 (50 nM) alone or a combined treatment for 48 hours. Apoptosis cells were 
detected with an FITC Annexin-V/PI apoptosis assay for flow cytometry. Combined 
treatment of either cell line with YM155 and radiation occurred in an increase in the 
number of apoptotic cells after a 48 hour-incubation, which was greater than the sum of the 
increase induced by YM155 or radiation alone. 
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Figure 3-6. Clonogenic survival assay of cell lines that treated with/without YM155. Cells 
were incubated with YM155 (50 nM) or a vehicle for 48 hours, exposed to the indicated 
doses of radiation, and then incubated in drug-free medium for 7 to 10 days. (a) CNSC1 
treated with YM155 decreased SF2 from 60% ± 4% to 52% ± 5%. (b) CNSC1-IR treated 
with YM155 decreased SF2 from 83% ± 3% to 62% ± 2%. 
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(4) Radiosensitizing effect of other molecular targeted agents in the radioresistant canine 
nasal squamous cell carcinoma cell line (CNSC1-IR) 
 
1) Cell growth inhibition assay of each molecular targeted agent 
   Cell growth inhibition assay were performed with YM155, celecoxib, toceranib and 
gefitinib in CNSC1 and CNSC1-IR cells. Cell growth activities were determined by a 
WST-8 colorimetric assay. The cell growth inhibition curves were shown in Figure 3-7. For 
each drugs, the IC50 value was defined as the drug concentration resulting in 50% of 
maximal growth inhibition as determined from the dose-response curve. The IC50 value of 
YM155 in CNSC1 and CNSC1-IR was 90.2 nM and 42 nM, respectively (Figure 3-7a). The 
IC50 value of celecoxib in CNSC1 and CNSC1-IR was 48.3 μM and 49.2 μM, respectively 
(Figure 3-7b). The IC50 value of toceranib in CNSC1 and CNSC1-IR was 4.1 μM and 5.4 
μM, respectively (Figure 3-7c). Additionally, the IC50 value of gefitinib in CNSC1 and 
CNSC1-IR was 8.3 μM and 6.1 μM, respectively (Figure 3-7d). 
 
2) Effect of the molecular targeted agents on radiation-induced apoptosis in CNSC1-IR 
cells 
   We also examined the effect of celecoxib (50 μM), toceranib (1 μM) and gefitinib (5 μM) 
on radiation-induced apoptosis in the radioresistant cell line, CNSC1-IR, with the use of an 
FITC Annexin-V/PI apoptosis assay for flow cytometry. Combined treatment with each 
molecular targeted agent and radiation (6 Gy) also resulted in an increase in the number of 
apoptotic cells after a 48 hour-incubation. However, the combined treatment of YM155 and 
radiation occurred the greatest numbers of radiation-induced apoptosis cells than of other 
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agents and radiation (Figure 3-8). 
 
3) Radiosensitizing effect of each molecular targeted agent in CNSC1-IR cells 
   We also examined the radiosenistizing effect of celecoxib, toceranib and gefitinib in 
CNSC1-IR cell line by clonogenic survival assay. Cells were incubate with celecoxib (50 
μM), toceranib (1 μM) and gefitinib (5 μM) or a vehicle (control, 0.1% DMSO) for 48 
hours, exposed to the radiation doses of 2 to 8 Gy, and then incubated in drug-free medium 
for 7 to 10 days for determination of colony-forming ability (Figure 3-9). The CNSC1-IR 
cells that treated with celecoxib decreased the SF2 of 83% ± 3% to 68% ± 4%. Toceranib 
and gefitinib also decreased the SF2 of CNSC1-IR, but they were not significant. YM155 
showed the greatest effect of radiosensitizing among these agents for CNSC1-IR cells. 
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Figure 3-7. Cell growth inhibition assay of YM155, celecoxib, toceranib and gefitinib in 
CNSC1 and CNSC1-IR cells. Cell growth activities were determined by a WST-8 
colorimetric assay. (a) YM155, the IC50 value of CNSC1 was 90.2 nM; CNSC1-IR was 42 
nM. (b) Celecoxib, the IC50 value of CNSC1 was 48.3 μM; CNSC1-IR was 49.2 μM. (c) 
Toceranib, the IC50 value of CNSC1 was 4.1 μM; CNSC1-IR was 5.4 μM. (d) Gefitinib, the 
IC50 value of CNSC1 was 8.3 μM; CNSC1-IR was 6.1 μM. 
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Figure 3-8. Comparison of apoptotic rate of CNSC1-IR cells treated with an irradiation of 6 
Gy or molecular targeted agent alone or a combined treatment. Cells were incubated for 48 
hours. Apoptosis cells were detected with an FITC Annexin-V/PI apoptosis assay for flow 
cytometry. Combined treatment with each molecular targeted agent and radiation (6 Gy) 
resulted in an increase in the number of apoptotic cells. The combined treatment of YM155 
and radiation occurred the greatest increased folds of radiation-induced apoptosis cells than 
of other agents and radiation. 
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Figure 3-9. Comparison of radiosensitizing effect of YM155, celecoxib, toceranib and 
gefitinib in CNSC1-IR cells by clonogenic survival assay. Cells were incubated with (a) 
YM155 (50 nM), (b) Celecoxib (50 μM), (c) Toceranib (1 μM) and (d) Gifitinib (5 μM) for 
48 hours, exposed to the indicated doses of radiation, and then incubated in drug-free 
medium for 7 to 10 days.  
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4. DISCUSSION 
 
   The establishment of growing cell lines from solid tumors provides a useful tool for 
research on various facets of tumor cell biology. Human cancer cell lines have been 
established for researching frequently [95]. It is important to that using spontaneously 
occurring canine tumors as translational models of diseases necessitates corresponding 
tumor cell lines [89]. Canine tumor cell lines have been used to characterize the tumor cells 
[5, 37, 63] and to study novel therapy in vitro and in vivo [38, 105]. Squamous cell 
carcinoma (SCC) is one of common type of tumor in canine malignancies. We found the 
prognostic factors and radiosensitivity of nasal tumor in each type of nasal carcinomas in 
Chapter I. Nasal SCC showed a worse response rate and prognosis comparing other types of 
nasal carcinoma. The establishment of CNSC1 as canine nasal SCC cell line provides one 
tool for understanding the mechanism of malignancy and of radioresistance of SCC in 
veterinary research. CNSC1 cell line has been sub-cultured over 70 passages. 
   Ionizing radiation may cause damage of DNA in cells. They undergo cell death when 
the DNA damage is irreparable [28, 62]. Radiation-induced cell death is classified into 
“reproductive death” and “interphase death”. Reproductive death is the loss of the 
proliferative ability of the cell. Interphase cell death is the death of irradiated cells before 
they enter in mitosis. It commonly causes cell death through apoptosis [62]. Clonogenic 
survival assay determines the ability of a cell to proliferate, thereby retaining its 
reproductive ability to form a colony. FITC Annexin-V staining is commonly used to detect 
the loss of membrane integrity if the cells undergo death resulting from either apoptotic or 
necrotic processes. Clonogenic survival assay and FITC Annexin-V staining were 
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performed to detect cellular radiosensitivity in this chapter. 
   A radioresistant subclonal cell line (CNSC1-IR) was established for comparing the 
character with the control cell line (CNSC1). Radiation may cause apoptosis for killing 
cancer cells [78, 87, 102]. A close correlation between the rate of spontaneous apoptosis and 
of radiation-induced apoptosis has been proved, and the spontaneous apoptotic rate of 
untreated tumor cell line also correlated with the radiosensitivity [78]. A higher level of 
spontaneous apoptosis was detected in the sensitive control cell line, CNSC1, (0.93% ± 
0.13%) compared with the radioresistant CNSC1-IR cells (0.5% ± 0.11%). A higher level of 
radiation-induced apoptosis was also observed in CNSC1 cell line at 24, 48 and 72 hours 
after treating with radiation. It was suggested that the apoptosis induced by irradiation was 
altered in the radioresistant CNSC1-IR, which was also consistent with the typical 
radioresistant phenotype. The different intrinsic radiosensitivities in human lung or 
colorectal carcinoma cells have also found higher levels of spontaneous apoptosis to show 
more sensitivity to radiation in vitro [78, 87]. 
   Survivin, a member of the IAP family, involves in both inhibition of apoptosis and 
control of cell division. Its anti-apoptotic function seems to be related to its ability to inhibit 
caspase-related proteins directly or indirectly. However, it has become increasingly clear 
that the role of survivin in response to ionizing radiation far exceeds a simple inhibition of 
apoptotic pathway [41, 78, 72, 111]. A weak but significant negative correlation was also 
found between the level of survivin expression and spontaneous apoptosis rate in canine 
nasal carcinoma tissues (r = -0.312; P = 0.028) in Chapter II. Our in vitro study results 
could be confirmed that CNSC1-IR cells expressed a higher level of survivin protein and 
also showed a lower rate of spontaneous and radiation-induced apoptosis. And it was 
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resistant to irradiation as determined performing the clonogenic survival assay (Figure 3-3 
and 3-4). These results are in line with a study on human colorectal cancer cells in vitro, 
where an inverse relationship between survivin expression and radiosensitiv was also found 
[78]. Therefore, survivin expression is strongly suggested to be a predictor for cellular 
radiosensitivity. 
   YM155 is a small molecule agent that specifically inhibits survivin expression in 
various types of tumor cell line in vitro [64]. Two previous studies have been reported that 
YM155 increased the sensitivity of human non-small cell lung cancer and esophageal 
squamous cell carcinoma cells to radiation in vitro and in vivo [39, 72]. Iwasa et al. 
indicated that radiosensitization of tumor cells by YM155 was associated with increased 
activity of caspase-3, suggesting that YM155 sensitized tumor cells to radiation partly by 
enhancing radiation-induced apoptosis [39]. YM155 is also able to abrogate G2 checkpoint 
in response to radiation. Shortening of the G2 checkpoint leads to decreased repair of 
radiation-induced damage before next cell division [72]. Our result revealed that YM155 
markedly potentiated the decrease in canine nasal SCC cell survival induced by radiation. 
Our finding suggested that YM155 suppresses the level of survivin protein and then 
increases radiation induced-apoptosis to enhance the radiosensitivity of the canine nasal 
SCC cells. 
   In a broad study of YM155 antitumor activity in a variety human cell lines, Nakahara et 
al. have found a correlation between survivin levels and IC50 values. The sensitivity of cell 
line to YM155 was related with high level of survivin [64]. Our result also showed that the 
radioresistant nasal SCC cells, CNSC1-IR, with higher level of survivin protein had lower 
value of IC50 (42 nM) than the lower survivin level cells, CNSC1 (90.2 nM) did. CNSC1-IR 
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cells revealed more sensitivity to YM155. 
   Although some studies have been reported about the radiosensitizing effects exerted by 
COX-2 selective inhibitors on a variety of human cancer cells, the mechanisms underlying 
these effects have yet to be clearly understood [85, 101, 110]. Celecoxib enhanced 
radiosensitivity of canine nasal SCC cells and increased the apoptotic cells with a 
combination of radiation in this chapter. Previous studies have shown that an increase of 
radiosensitivity induced by celecoxib in an NPC cell line is associated with G2-M phase 
arrest and apoptosis induction [110]. Furthermore, celecoxib was related to the 
down-regulation of not only COX-2 but also VEGF in human cervical cancer cells [101]. 
Irradiation and COX-2 inhibition seemed to have a synergistic inhibitory effect on tumor 
cell proliferation and tumor angiogenesis. 
   Toceranib phosphate is a tyrosine kinase inhibitor (TKI) targeting the VEGFR-2, 
PDGFR, Kit, and Flt-3, which inhibits the PI3K/Akt signaling pathway then induces cell 
apoptosis [56, 99]. Toceranib did not directly sensitize cytotoxicity in CNSC1 cells (IC50 > 
1 μM). Hence, it also did not show a radiosensitizing effect in our study. However, 
toceranib was originally developed as an anti-angiogenic agent as inhibition of VEGFR and 
PDGFR family members limit angiogenesis in murine tumor models [56]. Anti-angiogenic 
activity is not able to show in our in vitro study. Additional in vivo or clinical study is 
needed. On the other hand, EGFR inhibitor (cetuximab) plus radiotherapy is superior to 
radiotherapy alone in increasing both the duration of local control and survival in human 
head and neck cancer [12]. Gefitinib has also found to enhance radiosensitivity of human 
lung cancer cells by inhibiting the activation of the anti-apoptotic and proliferative signal 
transduction pathways [80]. However, gefitinib is only effective in cancers with mutated 
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and overactive EGFR. CNSC1-IR was not analyzed the mutation of EGFR, there is 
therefore no evidence for enhancing radiosensitivity in our study. Our result still provides a 
rationale for future preclinical and clinical investigation of therapeutic efficacy of molecular 
targeted agents in combination with radiation therapy.   
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5. SUMMARY 
 
   We established a nasal squamous carcinoma cell line that called CNSC1 from a dog, and 
also developed a radioresistant subclonal cell line (CNSC1-IR). They provide a useful tool 
for research on canine tumor cell radiobiology. Our in vitro study showed that CNSC1-IR 
cells expressed a higher level of survivin protein and also had a lower rate of spontaneous 
and radiation-induced apoptosis than the control CNSC1 cells. Therefore, survivin in our 
study is considered to play a role for cellular radiosensitivity. 
   YM155 suppressed the level of survivin protein and then increased radiation 
induced-apoptosis to enhance the radiosensitivity of the canine nasal SCC cells. It showed 
that YM155 sensitized CNSC1 and CNSC1-IR cells to radiation in vitro. Our results 
provided a rationale for future preclinical and clinical investigation of therapeutic efficacy 
of survivin inhibition in combination with radiation therapy.  
   On the other hand, COX-2 inhibitor, celecoxib, was also observed a synergy effect of 
combination with radiation. However, neither multi-targeted TKI (toceranib) nor EGFR 
inhibitor (gefitinib) showed to alter the radiosensitivity of CNSC1-IR cells in vitro.  
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CONCLUSION 
 
   Radiation therapy has become widely available and high in demand in companion 
animals with cancers. Recently, there has been an increase in information on its 
effectiveness in the treatment of a number of different tumor types. Canine nasal tumors are 
considered one of the most tumor types frequently treated with radiation therapy. Nasal 
tumors are uncommon but they are nearly all malignant. Canine nasal tumors of carcinomas 
are more common than those of sarcomas. Clinical and immunohistochemical prognostic 
factors were evaluated in dogs with nasal carcinoma. Moreover, the mechanisms of 
radioresistance and radiosensitizing effect were also analyzed for a nasal SCC cell line in 
this thesis. 
   In Chapter I, we attempted to describe the outcomes for dogs with nasal carcinoma 
based on clinical variables. We then compared the survivals for dogs that were treated with 
such radiation therapy in RGU. The median survival time for all patients with nasal 
carcinoma treated with radiation therapy in our study was approximately 8 months (241 
days), whereas the dogs that did not receive treatment only survived 3.1 months (95 days). 
Dogs that were diagnosed with SCC had a worse response rate (20%) to radiation compare 
other carcinoma subtypes. The dogs with SCC also found to have a shorter survival times 
(178 days) in our study. Additional negative prognostic factors for progression-free 
survivals (PFS) or overall survival times were observed in this chapter. In clinical signs and 
CT findings, presence of nasal discharge, facial deformity, exophthalmos at initial 
presentation, orbital or subcutaneous involvement and cribriform plate destruction were 
significantly related with PFSs. Dogs with metastasis had significantly shorter PFS than 
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those without metastatic disease. Dogs with a partial response were closely correlated with a 
longer PFS than those with a stable disease. Furthermore, dogs without nasal discharge or 
with exophthalmos, neurological abnormalities, orbital involvement and cribriform plate 
destruction were also highly associated with shorter overall survival times. Additionally, 
dogs with an age less than 11 years had longer survival than dogs with an age greater than 
11 years. Presence of metastasis and RT response also had significant correlations with the 
survival times.  
   In Chapter II, we evaluated the expression of tumor markers (Ki-67, survivin, EGFR, 
VEGF and COX-2) in canine nasal carcinoma through an immunohistochemical staining. 
Survivin (89.6%), EGFR (88.1%), VEGF (97%), and COX-2 (82.1%) were expressed in 
canine nasal carcinoma samples that were biopsied before treatment. Overexpression of 
survivin was observed in the dogs with a late clinical stage and worse response to radiation. 
It also yielded shorter survival times after radiation therapy. Therefore, survivin in our study 
is strongly suggested a valuable prognostic factor for predicting the outcome of canine nasal 
carcinomas with radiation treatment. On the other hand, although EGFR seemed to show a 
correlation with the treatment response in the dogs that treated with radiation, it was 
insignificant. However, high-EGFR dogs showed significantly shorter overall survival than 
low-EGFR dogs. High level of VEGF was strongly associated with an advanced-stage in 
nasal carcinoma but it was not related with survival. COX-2 expression was not associated 
with clinical features, treatment response and even survivals in our results. Additionally, 
high level of Ki-67 was closely correlated with an aggressive tumor. Therefore, high-Ki67 
dogs were observed to have shorter survivals after treating with radiation.  
   In Chapter III, we established a cell line of canine nasal squamous cell carcinoma 
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(CNSC1) and a radioresistant subclone cell line (CNSC1-IR). In this in vitro study, 
CNSC1-IR cells showed a higher level of survivin protein and a lower rate of spontaneous 
and radiation-induced apoptosis than the control CNSC1 cells. Therefore, survivin 
expression is considered to play a role for cellular radiosensitivity. YM155 suppressed the 
level of survivin protein and then increased radiation induced-apoptosis to enhance the 
radiosensitivity of the canine nasal SCC cells. It showed that YM155 sensitized CNSC1 and 
CNSC1-IR cells to radiation in vitro. Our results provided a rationale for future preclinical 
and clinical investigation of therapeutic efficacy of survivin inhibition in combination with 
radiation therapy. On the other hand, COX-2 inhibitor, celecoxib, also found a synergy 
effect of combination with radiation. However, neither multi-targeted TKI (toceranib) nor 
EGFR inhibitor (gefitinib) was shown to alter the radiosensitivity of CNSC1-IR cells in 
vitro. 
   Based from the results described above, survivin is considered a strong prognostic 
significance in dogs with nasal carcinoma. However, additional study of the efficacy of 
radiation therapy combined with survivin inhibition for improving patient prognosis is 
necessary, especially in advanced-stage tumors and those that often have a poor response to 
radiation therapy. This thesis also provided a rationale for future preclinical and clinical 
investigation of therapeutic efficacy of molecular targeted therapeutic agents in a 
combination with radiation therapy.  
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